Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent

Samya Chakravorty^{1, 2, 3, 4, *}, Babi Ramesh Reddy Nallamilli⁵, Satish Khadilkar^{6, 7, 8}, 1 Madhubala Singla^{6,7,8}, Ashish Bhutada⁶, Rashna Dastur⁹, Pradnya Gaitonde⁹. Laura 2 Rufibach¹⁰, Logan Gloster^{1, 4}, Madhuri Hegde^{4, 5, *} 3 4 ¹ Emory University Department of Pediatrics, Atlanta, GA, USA 5 ² Emory University Department of Human Genetics, Atlanta, GA, USA 6 ³ Division of Neurosciences, Children's Healthcare of Atlanta, GA, USA 7 ⁴ School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA 8 ⁵ PerkinElmer Genomics, Global Laboratory Services, Waltham, MA, USA. 9 ⁶ Department of Neurology, Bombay Hospital, Mumbai, Maharashtra, India 10 ⁷ Department of Neurology, Sir J J Group of Hospitals, Grant Medical College, Mumbai, 11 12 Maharashtra, India ⁸ Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India 13 ⁹ Centre for Advanced Molecular Diagnostics in Neuromuscular Disorders (CAMDND) Mumbai, 14 15 Maharashtra, India ¹⁰ Jain Foundation, Seattle, WA, USA 98115 16 17 18 19 * Correspondence: 20 21 Samya Chakravorty samya.chakravorty@emory.edu 22 23 24 Madhuri Hegde madhuri.hegde@perkinelmer.com 25 26 **Lead Contact:** Samya Chakravorty (samya.chakravorty@emory.edu) 27 28 Manuscript word count: 5507, Number of Figures: 3, Number of Tables: 6 29 30 Keywords: Inherited Myopathies, LGMD, Exome Sequencing, Next Generation Sequencing, 31

32

Molecular Diagnostics, India

34 **ABSTRACT** 35 **Objective** 36 37 Inherited myopathies comprise more than 200 different individually rare disease-subtypes but when 38 combined together have a high prevalence of 1 in 6000 individuals across the world. Our goal was to 39 determine for the first time the clinical- and gene-variant spectrum of genetic myopathies in a 40 substantial cohort study of the Indian subcontinent. 41 Methods 42 In this cohort-study, we performed the first large clinical exome sequencing (ES) study with 43 phenotype correlation on 207 clinically well-characterized inherited myopathy-suspected patients from the Indian subcontinent with diverse ethnicities. 44 45 Results 46 Clinical-correlation driven definitive molecular diagnosis was established in 49% (101 cases; 95%) 47 CI, 42%-56%) of patients with the major contributing pathogenicity in either of three genes, GNE 48 (28%; GNE-myopathy), DYSF (25%; Dysferlinopathy) and CAPN3 (19%; Calpainopathy). We 49 identified 65 variant alleles comprising 37 unique variants in these three major genes. 78% of the 50 DYSF patients were homozygous for the detected pathogenic variant suggesting the need for carrier-51 testing for autosomal-recessive disorders like Dysferlinopathy that are common in India. We describe 52 the observed clinical spectrum of myopathies including uncommon and rare subtypes in India: Sarcoglycanopathies (SGCA/B/D/G), Collagenopathy (COL6A1/2/3), Anoctaminopathy (ANO5), 53 54 telethoninopathy (TCAP), Pompe-disease (GAA), Myoadenylate-deaminase-deficiency-myopathy 55 (AMPD1), myotilinopathy (MYOT), laminopathy (LMNA), HSP40-proteinopathy (DNAJB6), Emery-Dreifuss-muscular-dystrophy (EMD), Filaminopathy (FLNC), TRIM32-proteinopathy (TRIM32), 56 57 POMT1-proteinopathy (*POMT1*), and Merosin-deficiency-congenital-muscular-dystrophy-type-1 58 (LAMA2). 13 Patients harbored pathogenic variants in >1 gene and had unusual clinical features 59 suggesting a possible role of synergistic-heterozygosity / digenic-contribution to disease presentation and progression. 60 **Conclusions** 61 62 Application of clinically-correlated ES to myopathy diagnosis has improved our understanding of the 63 clinical and genetic spectrum of different subtypes and their overlaps in Indian patients. This, in turn, 64 will enhance the global gene-variant-disease databases by including data from developing 65 countries/continents for more efficient clinically-driven molecular diagnostics. 66 67 68 69 70

INTRODUCTION

To date, >250 genes are associated with various inherited neuromuscular disorders (NMDs) (1-4) comprising a broad heterogeneous group of genetic myopathies. However, significant numbers of affected patients remain without a definitive molecular diagnosis due to novel gene or multiple gene associations with disease (5, 6). The autosomal-dominant forms represent <10% of all genetic myopathies (6-8) and are usually associated with milder clinical-presentation and adult-onset. Whereas, for the more common autosomal-recessive forms, multiple monogenic subtypes have been identified including those that make up the limb-girdle muscular dystrophies (LGMDs) (5, 9). Definitive molecular diagnosis is a prerequisite for patient participation in clinical-trials or precision medicine treatment and management. Hence, it is important to understand the genetic etiologies and subtype prevalence in different populations to enhance global variant databases for more efficient and accurate gene-variant classification and diagnosis.

Several studies reported the use of next-generation-sequencing (NGS) for molecular diagnosis in small/large genetic myopathy patient-cohorts in different countries (6, 10-12). But the application of exome sequencing (ES) for a large cohort of myopathy patients from the Indian subcontinent has not been reported previously. Similar to the rising awareness of the importance of African genomes or exomes in global public health and enhancing public databases, it is important to study the populations of the Indian subcontinent and Asia as a whole comprising of the largest proportion of the world population which offers diverse ethnic and genetic backgrounds (13-16). Moreover, the sociocultural belief systems and traditions have led to community marriages, consanguinity and intracommunal exogamy in sections of the Indian population. Here, we performed the first large-scale ES study on 207 clinically well-characterized inherited myopathy-suspected patients of diverse ethnicities from the Indian subcontinent to identify the causative gene and disease-subtypes. Our results yield interesting observations on Indian myopathy clinical and gene-variant landscape and approaches to both clinical and genetic diagnosis in muscular dystrophy and myopathy in general.

MATERIALS AND METHODS

Standard Protocol Approvals, Registrations, and Patient Consents

- Written, informed consent was obtained from all individuals or minors' parent or legal guardian or next of kin for the publication of any potentially identifiable images or data included in this article.
- Written informed consents were obtained from all participants of the study for all procedures
- according to approved Ethics committee Institutional Review Board protocol. All participants
- 110 (including parents or legal guardians in case of minor patients) were provided pre- and post-test
- routine genetic counseling.

114

Patients and Study Design

- In an effort to understand the genetic basis of myopathies, over a 3-year period (2016-2019) a total of
- 207 patients with clinical suspicion of an inherited myopathy were recruited (see Questionnaires in
- Supplementary Material) based on the following inclusion and exclusion criteria: Inclusion criteria:
- Patients with a suspected clinical diagnosis of genetic myopathy. Exclusion Criteria: 1. Patients with
- 119 confirmed diagnosis of Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular
- dystrophy (FSHD), myotonic dystrophy (DM1 and DM2), mitochondrial myopathy and Acquired
- myopathies. DMD, myotonic dystrophies and FSHD were genetically diagnosed. Mitochondrial
- myopathies were diagnosed based on muscle biopsy immunohistochemistry and/or genetic diagnosis.
- We used modified Gomori trichrome, cytochrome oxidase (COX) and nicotinamide adenine
- dinucleotide (NADH) stains for the demonstration of mitochondrial dysfunction, supported by
- electron microscopy as needed. There was no age restriction and the patients were recruited from
- across the Indian subcontinent at a single tertiary care hospital.

127

128129

130

131

132

133

134

135

136

137

138 139

140

141

142

143

144

145

Clinical Evaluation

All patients underwent comprehensive clinical evaluation. Clinical details including age of onset, initial symptoms, region in which weakness started first, and functional status of the patient was collected whenever available for all patients recruited in the study. Pattern of weakness including upper limbs or lower limbs, or both, proximal or distal or both, symmetrical or asymmetrical, and differential weakness, was determined. Detailed pedigree analysis was performed. Available affected family members were examined. Detailed history regarding the origins and ancestry and marriage customs practiced in the specific ethnic community was documented. Patients underwent detailed clinical examination with focus on the motor system. Hypertrophy, atrophy of muscles was determined from inspection. Neck flexors, extensors and other total 16 pairs of muscles (trapezius, deltoid, serratus anterior, biceps, brachioradialis, triceps, wrist flexors and extensors, ileopsoas, hip adductors, abductors, extensors, quadriceps, hamstrings, tibialis anterior, gastrocnemius-soleus) were examined as per the MRC grading system of 0 to 5. Small muscles of hands, feet, and paraspinal muscle were also examined. Serum creatine kinase was determined at the time of presentation prior to electromyography. Electromyography and nerve conduction studies were performed in all patients. Electrocardiography was done in all patients and Echocardiography was done in selected symptomatic patients.

146

147

148

Muscle Biopsy Procedure

- Muscle biopsy procedure was performed for only the consenting patients as per routine methodology.
- Muscle biopsy was performed from clinically affected muscle with power between MRC grades 3 to
- 4. Biopsy specimens were snap frozen in chilled isopentane for frozen sections and later taken in
- 152 formalin for paraffin embedding. Routine assessment of morphological changes was carried out on
- frozen and paraffin sections. Biopsy specimens from those patients who consented for the procedure
- were grouped into dystrophic, myopathic, dystrophic with inflammation, myositis, mixed

- 155 (neurogenic and myopathic) changes, and some no diagnosis. Histochemical studies were done using
- 156 ATPase and NADH-TR (nicotinamide adenine dinucleotide (NAD) + hydrogen (H) and tetrazolium
- 157 reductase) stains. Frozen sections of 6 microns were stained with dystrophin 1 (C terminus-mouse
- monoclonal Dy8\6C5), dystrophin 2 (mid-rod domain mouse monoclonal Dy4\6D3), dysferlin 158
- 159 (mouse monoclonal NCL-Hamlet-2), and α (Ad1\20A6), β (Bsarc\5B1), γ (35 DAG\21B5) and δ
- 160 (Dsarc 3\12C1) sarcoglycan antibodies (Novocastra labs), using peroxidase method and standard

161 controls.

162 163

164

165

167

171

175

181

184

185

187

188

191

195

196

197

198

199

200

201

Molecular Diagnosis by Exome Sequencing

Exome sequencing was performed in a Clinical Laboratory Improvement Amendments and College 166 of American Pathologists (CLIA-CAP)-certified laboratory. Peripheral intravenous blood was collected from enrolled patients into 10-ml commercial tubes containing ethylene-diamine tetraacetic 168 acid (EDTA). These samples were shipped immediately overnight on ice to our laboratory for further 169 analysis. DNA was extracted from whole blood using the Qiagen genomic DNA extraction Kit 170 according to the manufacturer's instructions. We performed exome sequencing using Agilent V5Plus exome capture kit to identify disease causative variants. Sequencing was performed using the 172 Illumina HiSeq 2500 sequencing system with 100-basepair (bp) paired-end reads (similar to 173 bidirectional Sanger sequencing), with an average coverage of 100X in the target region. The target 174 region includes the exon and 10 bp of flanking intronic region. NextGENe software mapped the DNA sequence reads to the published human genome build UCSC hg19 reference sequence. Primary 176 data analysis was also performed using Illumina DRAGEN Bio-IT Platform v.2.03. Secondary and 177 tertiary data analysis was also performed using PerkinElmer's internal ODIN v.1.01 software for 178 SNVs and Biodiscovery's NxClinical v.4.3 or Illumina DRAGEN Bio-IT Platform v.2.03 for copy 179 number variant (CNV) and absence of heterozygosity (AOH). Reads were aligned and filtered as 180 described previously (17, 18). In short, in the filtering process, variants in genes that are not relevant to the patient's clinical phenotypes were filtered in the clinical setting using population-wide minor 182 allele frequency, predicted effect on protein function or splicing, literature evidence, and disease-183 variant databases such as the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk), ClinVar (http://www.clinvar.com), Online Mendelian Inheritance of Man (https://www.ncbi.nlm.nih.gov/omim), genome Aggregation Database (gnomAD: 186 https://gnomad.broadinstitute.org/), and using our internal Emory Genetics Lab (EGL) EmVClass database (http://www.egl-eurofins.com/emvclass/emvclass.php). Variants that do not meet QC metrics, such as those with poor coverage (<20×), were considered less likely to be real, treated as 189 false positives, and therefore filtered. Variants with a minor allele frequency of >0.01 are 190 polymorphisms by definition and less likely to be pathogenic. Silent changes and intronic variants beyond the consensus splice donor/acceptor sequences or beyond the 10bp intronic flanking 192 sequences are less likely to be pathogenic and were filtered in the analysis unless a known clinically 193 significant rare deep-intronic variant is identified. Rare single nucleotide variants (SNVs) meeting 194 internal quality assessment guidelines are confirmed by Sanger sequence analysis.

Molecular diagnosis was performed by classifying variants with clinical data correlation to identify most likely causal disease gene and as per American College of Medical Genetics and Genomics (ACMG) guidelines (19) and with clinical data correlation. Diagnostic yield was calculated based on definitive diagnosis of patients harboring pathogenic or likely pathogenic variants in autosome-recessive/dominant, and X-linked myopathy genes. Prevalence of each identified myopathy subtype identified by our clinical exome sequencing diagnostic program was established and compared. When rare reportable variants in our study were not found in NIH ClinVar

(https://www.ncbi.nlm.nih.gov/clinvar/), nature of variant, literature evidence and correlation with established specific clinical symptoms of the patient's myopathy was used to identify most likely causal gene and to classify the variant, keeping in mind ACMG guidelines. When no literature evidence was found, the variant was classified based on nature of variant such as nonsense variant or frameshift variant causing a premature stop codon or a stop-loss or a large deletion or duplication in genes known to affect by loss of function modality, as well as correlation with established specific clinical symptoms of the patient's myopathy. High-confidence rare variants were taken as novel when not found in public databases and included in the analysis to interpret relevant disease type causality with clinical correlation. Patient cases with variants of uncertain significances (VUSs) were not included in the molecular diagnostic yield calculations.

212 213

202

203

204

205 206

207

208

209

210

211

214

215

216

217

RESULTS

218 219

220

Molecular diagnosis of recruited patients

- 221 A total of 207 unrelated myopathy-suspected patients were recruited in the current study from diverse
- 222 regions of India with different ethnicities and religion, as well as varied social and marriage customs.
- 223 Molecular diagnosis was established in 49% (101/207; 95% CI, 42%-56%) of the patients with the
- 224 majority having pathogenic variants identified in one of the following genes, GNE (31%; 31/101),
- 225 DYSF (27%; 27/101), or CAPN3 (19%; 19/101), indicating that these genes are the major
- 226 contributors to genetic myopathy in India (Figure 1). Autosomal-recessive forms were much more
- 227 frequent constituting 95/101 (94%) of the genetically-diagnosed patients. Uncommon autosomal/X-
- 228 linked recessive-subtypes identified were: 5 sarcoglycanopathies (LGMD R3-R6; 5%), 3
- 229 anoctaminopathies (LGMD R12 anoctamin-related; 3%), 2 myoadenylate-deaminase-deficiency-
- 230 myopathies (2%), 2 Pompe disease (2%), 2 telethoninopathies (LGMDR7 telethonin-related; 2%), 1
- 231 X-linked Emery-Dreifuss-muscular-dystrophy (EDMD1 emerin-related; 1%), 1 Merosin-deficiency-
- 232 congenital-muscular-dystrophy-type 1 (MDC1 or LGMDR23 laminin α2-related; 1%), 1 POMT1-
- 233 proteinopathy (LGMDR11 POMT1-related; 1%). Autosomal-dominant-subtypes were less common
- 234 with 3 laminopathies (EDMD2; 3%), 1 myotilinopathy (Myofibrillar Myopathy; 1%), and 1 HSP40-235
- proteinopathy (LGMDD1 DNAJB6-related; 1%). 14 patients had no reportable variants and were
- 236 truly negative for this study.

237 We identified 65 variant alleles comprised of 37 unique variants in the three major genes 238 (GNE, DYSF, CAPN3). A total of 14 unique variants were identified in GNE (Figure 2A). The 239

present study confirmed the absence of a mutational hot-spot region in *GNE* in the Indian patients. 240 The majority of the variants detected in GNE (12) were missense variants located throughout the

241 GNE gene, suggesting an important role of missense changes in causing GNE-myopathy in people of 242

Indian subcontinent origin (Table 1). The most common pathogenic variants c.2179G>A (p/V727M)

- 243 and c.1760T>C/c.1853T>C (p.I587T/p.I618T) were detected in most of the *GNE* patients (Figure 2D) with extensive homozygosity observed for the c.1760T>C (p.I587T) common pathogenic
- variant. Only one nonsense variant c.385C>T (p.R129X), one frameshift variant c.397_398dupAT
- and no splice site variants were identified in GNE.
- 247 *CAPN3* and *DYSF* are the next major contributing genes in Indian genetic myopathy patients.
- Calpainopathy (CAPN3, LGMDR1) represents the most frequent LGMD-subtype worldwide (6, 20,
- 249 21), but was the second most common myopathy found in our cohort. No specific mutational hot
- spot was identified and all 14 identified unique variants in 9 patients were distributed throughout the
- 251 CAPN3 gene (Figure 2C). Homozygosity was observed in 4 out of 9 CAPN3 patients (45%) (Figure
- 252 2A,B).

261

262

278

- 253 The 9 unique variants identified in 9 *DYSF* patients were also distributed throughout the
- 254 DYSF gene. Interestingly, we found that 96% (26/27) of the individuals with a dysferlinopathy
- 255 molecular diagnosis were homozygous for the detected pathogenic variant (Figure 2B), explaining
- 256 why autosomal recessive disorders like dysferlinopathy are the more common form of inherited
- 257 myopathy found in India.
- In addition, the two Pompe genetically diagnosed Indian patients did not have either any
- 259 homozygous GAA variants or the leaky splice-variant c.-32-13T>G, that are more common in adult-
- onset Pompe in many other populations.

Clinical characteristics of genetically-diagnosed patients

- 263 Pictorial examples (Figure 3) and details of clinical features of common subtypes (Tables 1-2) and
- uncommon subtypes (Tables 3-4) of myopathies identified in our Indian cohort are provided. Cardiac
- involvement was observed in a total of 6 patients: one each for AMPD1, GAA, DYSF, LMNA, and
- 266 two GNE-myopathies. Patient# 2 (AMPD1) and 38 (LMNA: Laminopathy or EDMD) showed
- 267 atrioventricular conduction blocks, with AMPD1 patient showing 30% ejection fraction. Patient# 47
- 268 (DYSF) showed proximo-distal weakness and mild sub-clinical cardiomyopathy (ejection fraction
- 269 50%) resembling few reports of miyoshi myopathy (22, 23). Patient# 73 (GAA: Pompe disease) had
- 270 dilated cardiomyopathy with 32% ejection fraction and also showed respiratory involvement with
- breathlessness on exertion. Patient # 89 and 90 (GNE-myopathies) showed both sub-clinical
- 272 cardiomyopathy evidenced by mild reduction of ejection fraction on the 2D echocardiography.
- Among the 6 patients, only the patient # 73 (Pompe disease) showed breathlessness on exertion. Data
- on pulmonary function tests on any case were not available. Available muscle biopsy results
- indicated that 66% (31 out of 47) of the patients had dystrophic or myopathic changes with/without
- inflammation. A total of 4 patients were non-ambulatory and required wheel-chair assistance (Tables
- 277 1-4 and Table S1 in Supplementary Material).

Common Subtypes

- GNE myopathy, dysferlinopathy and calpainopathy were identified as the three most common
- subtypes of inherited myopathies. Normal range of creatine kinase (CK) in this study was 30-160
- 281 IU/L. The details of the pattern of clinical weakness and uncommon clinical features of these three
- groups are described below.

283	GNE-myopathy
284 285 286 287 288	The onset-age varied (16-60 years) in 17 females and 14 males. Total duration of illness was between 3 months and 30 years with lower limb onset in all except one with upper limb involvement simultaneously. Asymmetry at onset was seen in 13 patients. Creatine kinase (CK) levels ranged between 102-1986 IU/L. Two patients had loss of ambulation with long duration of illness (17 and 13 years).
289 290 291 292 293	Pattern of weakness: Most patients had conventional presentation with weakness affecting the tibialis-anterior (TA) maximally along with sparing of the quadriceps. With advancing duration of the disease, patients also showed a degree of weakness in the iliopsoas, adductors of thigh, hamstrings in lower-limbs and biceps and first dorsal interosseous muscles in the upper-limbs (denoted as D+P in Table 2).
294 295	<i>Rare clinical features:</i> Two patients had severe affection of proximal-muscles of the upper-limbs with winging, later into the illness (Table 2).
296	
297	Dysferlinopathy
298 299 300 301	Onset-age was 13-33 years in 15 males and 12 females. Duration of illness ranged from 1 to 17 years. Weakness began in the lower limbs of all patients: proximo-distal in 7 patients, only proximal in 21 patients, and only distal in the remaining 3 patients. Biceps lump was seen in 14 patients. CK levels highly varied and were between 1,018-26,740 IU/L.
302 303 304	Pattern of weakness: Most patients had proximal-onset of lower-limbs-weakness with maximum affection of iliopsoas, hip adductors, hamstrings, quadriceps, and gastrocnemius muscles. These patients had difficulty in walking on toes, wasting of calves and high CK-levels (Table 2).
305 306 307 308 309 310 311 312	Rare clinical features: Scapular winging and facial weakness was seen in 3 patients, in advanced stages of the disease. Asymmetry of weakness was seen in only 1 patient. This unusual patient had one pathogenic variant in the ANO5 gene along with a homozygous pathogenic variant in DYSF. Interestingly, this patient (patient #50 in Table 5) showed a phenotype common to both dysferlinopathy and anoctaminopathy (high CK, proximal and distal muscle weakness, asymmetrical weakness) and features unusual to both types (facial weakness). Presence of inflammation in muscle biopsy and absence of Dysferlin staining were the manifestations of dysferlinopathy at the histological level.
313	
314	Calpainopathy
315 316 317 318 319 320	Onset-age was 6 to 48 years in 10 males and 9 females. Duration of illness ranged from 1 to 27 years. Lower limb onset of weakness was seen in 21-patients, upper limbs in 2 and upper and lower limbs were simultaneously affected in 1 patient. The weakness was proximal in 18, proximo-distal in 5 and distal in 1 patient. Winging was present in 15/19 and tendo-achilis contractures were seen in 12/19-patients. Loss of ambulation developed in one patient after 27years into the illness. CK levels ranged from 690 to 7000 IU/L.

321 322 323	Pattern of weakness: Most patients had the conventional proximal weakness-onset in the lower-limbs. Maximum weakness was seen in the hip adductors, iliopsoas, hamstrings, tibialis anterior (TA) and serratus anterior muscles. Tendoachillis contractures and toe-walking was common.
324 325	Rare clinical features: One patient had diamond on quadriceps and biceps lump which is commonly described in dysfelinopathy. One other patient had mild facial weakness.
326	
327	
328	
329	Clinical features of genetically-diagnosed uncommon subtypes in India
330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347	The clinical features of the rare and uncommon genetically diagnosed subtypes found in this study have been provided in Table 4. These individual groups were small consisting of few or a single patient each and were comprised of sarcoglycanopathies (\$SGCA/SGCB/SGCD/SGCG)\$, collagenopathies (\$COL6A1/COL6A2/COL6A3)\$, anoctaminopathy (\$ANO5\$)\$, telethoninopathy (\$TCAP\$)\$, Pompe disease (\$GAA\$)\$, myoadenylate deaminase deficiency myopathy (\$AMPD1\$)\$, myotilinopathy (\$MYOT\$)\$, laminopathy (\$LMNA\$)\$, HSP 40 proteinopathy (\$DNAJB6\$)\$, Emery Dreifuss muscular dystrophy (\$EMD\$)\$, POMT1 proteinopathy (\$POMT1\$)\$, and merosin deficient congenital muscular dystrophy (\$LAMA2\$)\$. Interestingly, myoadenylate deaminase deficiency myopathy due to \$AMPD1\$ pathogenic variants was only identified in 2 patients out of 207 Indian patient cohort (\$\sim\$1%\$) suggesting lower prevalence among individuals in the Indian subcontinent area and Asians in general. These 2 patients showed heterogeneous symptoms. One had mild limb girdle weakness with slightly elevated CK-levels (\$65 IU/L\$). The second patient was wheelchair bound but with normal CK levels (73 IU/L). Along with having compound heterozygous pathogenic \$AMPD1\$ variants (\$c.242C>T\$ and \$c.133C>T\$)\$, the patient with the severe phenotype also harboured homozygous \$CAPN3\$ pathogenic variant (\$c.1793_1796delAAAC\$; patient # 1 or 6\$)\$, which could be associated with higher clinical severity. These \$AMPD1\$ cases suggest more heterogeneity in the nature of muscle weakness and clinical overlap of AMPD1-associated myopathy with limb-girdle features in the Indian population.
348 349 350 351 352	We also identified 21 patients carrying VUSs in <i>CAPN3</i> , <i>DYSF</i> , <i>GNE</i> , <i>COL6A1</i> , <i>COL6A2</i> , <i>COL6A3</i> , <i>FLNC</i> , <i>SGCB</i> , <i>TRIM32</i> genes that has strong clinical correlation with the gene and corresponding myopathy subtype of interest but without further information reclassify them as likely pathogenic or pathogenic (Table 6). These cases are not included in the diagnosed patients in our cohort. Further segregation and functional studies are needed to confirm these VUSs' pathogenicity.
354	Multigenic myopathies: a novel disease mechanism
355 356 357	Interestingly, 13 patients were identified with pathogenic variants in more than one myopathy genes (Table 5) all showing unusual presentations. We describe below such cases of multigenic unusual presentations identified in this study.
358 359 360	Patient# 118 with one pathogenic variant each in the <i>GNE</i> (OMIM# 603824) and myotilin (<i>MYOT</i> ; OMIM#604103) genes. His phenotype largely resembled GNE-myopathy with foot-drop and quadriceps-sparing. However, disease-onset was both proximal and distal which also could

resemble both subtypes. By the time foot-drop started, difficulty in rising from ground and low chairs had already developed. In this patient, both the genetic abnormalities could be contributing to the proximo-distal presentation resembling both autosomal-dominant myotilinopathy (24) as well as autosomal-recessive GNE-myopathy that has been reported to show early onset of proximal weakness mimicking LGMD especially with hamstring weakness (25). Muscle biopsy staining showed rimmed vacuoles, a common feature of both GNE-myopathy and *MYOT*-related myofibrillar myopathy. Myotilin immunostaining could have helped further but was not available.

Patient# 42 had pathogenic variants in the *GNE* gene and additionally harbored one likely pathogenic variant in the dysferlin (*DYSF*) gene. The phenotype was strongly suggestive of a GNE-myopathy, but had onset of proximal muscle weakness and presented a high CK level (1050 IU/L) which are a very well-known presentation of dysferlinopathy suggesting blended phenotype. GNE-myopathy patients are known to have proximal weakness only in later stages of illness. Muscle biopsy confirmed rimmed vacuoles but immunocytochemistry for dysferlin was not available, resembling GNE-myopathy more than dysferlinopathy.

Patient# 110 showed the most unusual symptoms: quadriceps-sparing and foot drop resembling GNE-myopathy, but with early and prominent development of scapular-winging and calf-hypertrophy. Interestingly, a heterozygous pathogenic variant in *CAPN3* (OMIM# 114240) and homozygous pathogenic variant in *POMT1* (OMIM# 607423) were present without any *GNE* variant. While the *CAPN3* variant can explain adductor, posterior thigh weakness and scapular winging, *POMT1* variants are known to be associated with hypertrophic calves (26) in limb-girdle muscular dystrophy (LGMDR11). Quadriceps-sparing and prominent foot-drop are unusual in the demonstrated genetic abnormalities.

Another patient (patient# 50) with a homozygous pathogenic variant in *DYSF* and a heterozygous pathogenic variant in *ANO5*, showed phenotypes of dysferlinopathy and anoctaminopathy that are representative of both subtypes (calf atrophy, CK of 6390 IU/L, combination of proximal and distal weakness, presence of inflammation in muscle-biopsy, asymmetry of muscle weakness, weakness in dorsiflexors of ankle joints, partial foot drop), and feature unusual to both (facial weakness).

We identified one patient clinically diagnosed with LGMDR2 but with an unexpected severe progression. This patient had pathogenic variants in both *DYSF* and *MYH2* genes (patient# 47). Heterozygous loss of *MYH2* coupled with complete loss of *DYSF* could be contributing to the rapid disease progression and severe phenotype of both proximal and distal muscle weakness along with cardiac-involvement observed in this individual.

Patient# 23 showed homozygous pathogenic variants in both *CAPN3* and *LIMS2* genes suffered from progressive weakness of hip and shoulder girdles. The phenotype consisted of scapular winging, lordosis, severe weakness of hip adductor muscles and mild tendo-achillis contractures, resembling calpainopathies. He also had mild calf hypertrophy. While transient or persistent calf hypertrophy has been documented in calpainopathies(27), it is also a feature of the *LIMS2*-patients. He did not have the triangular tongue or cardiomyopathy seen in *LIMS2*-patients.

Patient# 125 had one pathogenic variant each in both *LMNA* and *GNE* genes with limb-girdle pattern of weakness with calf hypertrophy and subclinical cardiac involvement in the form of atrioventricular conduction block. CK level was mildly raised (762 IU/L). All these features are in favor of autosomal-dominant laminopathy. Examination did not reveal any features suggestive of

GNE-Myopathy but since *GNE* variants can be segregated either recessively or dominantly, longitudinal patient and family natural history is being followed through.

Similar multigenic combinations of pathogenic variants were detected for *GNE*, *ANO5*, *MYOT*, *CAPN3*, *LIMS2*, *COL6A3*, *POMT1*, *CHRNG*, *EMD*, *PLEC*, *GAA*, *SGCB*, *DMD*, *DOK7*, and *LMNA* genes in a total of 13 individuals (Table 5).

410

407

408

409

411

412

413

DISCUSSION

- 414 Most of the inherited myopathies impose difficulties with physical activity, walking, poor quality of
- life and ultimately cause a heavy burden on both the affected individuals and their families.
- 416 Identifying the correct diagnosis of these inherited myopathies can aid in disease management,
- 417 treatment, and family planning. Clinical diagnosis is based on the distribution of predominant
- muscle weakness, inheritance mode and associated symptoms but is often highly elusive due to the
- overlap in clinical presentation. Therefore molecular diagnosis is necessary to confirm the identifying
- disease-causative gene. This study provides for the first time molecular diagnosis and clinical
- information on a fairly large cohort-size of genetic myopathies in patients of diverse ethnic
- backgrounds seen in the Indian subcontinent.

423 This cohort includes a large variety of inherited myopathies including GNE-myopathy, 424 varieties of LGMDs, collagenopathies, metabolic myopathies and related others which have a 425 significant phenotypic-overlap. GNE, DYSF, and CAPN3 are the three major genetic contributors to 426 these myopathies, in the Indian subcontinent. Even though we recruited patients from across the 427 Indian subcontinent, as the evaluation was performed in a major single center hospital, there could be 428 limitations to the interpretation of the prevalence. With upcoming or ongoing interventional or 429 natural history study clinical trials on these myopathy subtypes (https://clinicaltrials.gov/ct2/results?recrs=ab&cond=GNE+Myopathy+&term=&cntry=&state=&city 430 =&dist=, https://www.sarepta.com/science/gene-therapy-engine), this study will enable cohorts from 431 432 Indian subcontinent to be included in patient registries that, in turn, will enhance the clinical trials by 433 including different populations with varied ethnicities as well as better monitoring of trial efficacies. 434 Our diagnostic yield of 49% is considerably high with careful clinical correlation of the gene and rare 435 variant identified. Another reason for a high diagnostic yield in an Indian subcontinent cohort is the 436 high prevalence of consanguinity leading to greater homozygosity as found in all the three major 437 contributing genes: GNE, DYSF, and CAPN3 (Figure 2B). Moreover, our careful clinical pre-438 screening with inclusion criteria of genetic myopathies and excluding DMD, FSHD, DM1, DM2, 439 mitochondrial myopathies and acquired myopathies enabled a higher diagnostic yield and further 440 suggests the importance of phenotype correlation of clinical genetic testing results. The clinical 441 features of the three major genetic myopathies followed those mentioned in the literature to a large 442 extent such as GNE myopathy patients with weakness of the tibialis anterior muscles with sparing of 443 quadriceps, dysferlinopathy patients having gastrocnemius weakness and proximal weakness, and 444 calpainopathies having winging of scapulae and hip girdle weakness, mainly of adductor muscles. In 445 addition, GNE-myopathy patients in our cohort also had proximal weakness, possibly representing

advanced stages of the disease. The clinical features of the common and uncommon types are summarised in Tables 2 and 4, respectively.

Molecular findings related to GNE-myopathy patients identified in this study have been reported recently (28) with the most common pathogenic variant in our cohort being the c.1760T>C/c.1853T>C (p.I587T/p.I618T). This variant has recently been described with an ethnic founder effect (29, 30). Moreover, p.V727M is potentially a founder variant in Indian subcontinent since it was seen with high prevalence in our study and previous studies (31-33), and hence this variant is likely present in carriers at higher rates in the Indian subcontinent. This suggests the need for family tracing and carrier testing for inherited rare disorders such as GNE myopathy.

Calpainopathy (LGMDR1) was considered a strict autosomal-recessive LGMD-subtype for many years, but patients carrying specific single pathogenic deletion variants in the *CAPN3* gene are reported recently showing dominant disease segregation (6, 34) which was not identified in Indian patients in the current study.

Limb-girdle muscular dystrophy type 2B (LGMDR2) and Miyoshi myopathy (MM) caused by variants in the dysferlin gene, *DYSF* (35) are the two major clinical types of dysferlinopathy (36), characterized by proximal muscle-weakness, difficulty in running and climbing stairs, and increased fatigue (37). The higher (96%) homozygosity rate of pathogenic variant in *DYSF* gene explains why autosomal recessive disorders like dysferlinopathy are more common in Indian subcontinent. *DYSF* gene is much larger than some of the other genes such as *GNE* and *CAPN3*, the other two most prevalent myopathy forms in this study. Thus *DYSF* likely harbors more variants and therefore has a higher chance of homozygosity.

In this cohort many other more rare genetic myopathies were seen (Tables 3-4, Table S1 in Supplementary Material). Out of these, sarcoglycanopathies and collagenopathies were seen more frequently than other myopathies. The phenotypes of most myopathies were comparable to literature descriptions. There were some unusual clinical features and heterogeneity as well, such as that in AMPD1 associated myopathy where ranges from mild symptoms to severe limb-girdle features progressing fast to wheel-chair assistance and dilated cardiomyopathy were observed. Only 2 AMPD1-associated myopathy cases were identified in our Indian subcontinent cohort suggesting lower prevalence in Asia similar to what was shown before in the Japanese population (38), compared to being one of the most common genetic myopathies among Caucasians (1 in 50-100 individuals in general population)(39). The AMPD1 case with severe clinical symptoms also harboured homozygous pathogenic truncated variant in CAPN3 which may result in the greater disease severity. Further studies are needed to resolve the gene contributions and for better understanding of AMPD1's clinical significance. The diagnosis of myoadenylate deaminase deficiency is challenging given about 2% of muscle biopsies may have enzyme deficiency without clinical correlation (40-42). Deep phenotyping, immunohistochemical studies, western blot analysis or muscle imaging as well as functional studies are necessary to verify this group of myopathies.

The interesting finding of 13 patients with pathogenic variants in more than one myopathy gene (Table 5) and showing unusual presentations suggest a possible role of synergistic-heterozygosity and digenic contribution to unusual myopathies, similar to our recent finding in the US LGMD population (6). Multigenic combinations of pathogenic variants were detected involving 15 genes and 13 patients in this study suggest a high prevalence of synergistic heterozygosity in genetic myopathies. In some

cases, the phenotype exhibited features of both the genes (eg: GNE and MYOT, patient #118; DYSF and ANO5, patient# 50, in Table 5) and in some patient's phenotype favored one gene over the other (eg: patient# 125, Table 5). In some other case, there were clinical features unexplained by the identified genetic variants such as patient# 110 (Table 5) showing GNE-myopathy features without any GNE variant but pathogenic variants in POMT1 and CAPN3. Thus, when faced with an atypical phenotype of inherited myopathy, the possibility of pathogenic variants in more than one myopathic gene exists and clinical exome or genome sequencing should be considered. Moreover, result of genetic testing in such multigenic cases need to be interpreted cautiously and muscle immunostaining should be considered. For multigenic myopathies, some cases may be due to genetically unidentified or a novel gene, especially those with heterozygous VUS in genes known to cause only recessive diseases. With widespread use of extensive panels, focused or whole-exome, and genome-sequencing, more such instances will be unearthed, helping further understanding of the pathophysiology and expressions of the genetic abnormalities. Functional omics platforms such as RNA-sequencing, proteomics, and metabolomics (43, 44) of the muscle tissue and segregation studies are needed in these unusual cohorts, to understand the variable expressions of the genes at the effector organ and the phenotypic variability. We propose to carry out this work in future which is a current limitation of this study.

True negative findings for the 14 patients with myopathy clinical symptoms suggest the need for whole genome sequencing (WGS) in the future to discover new myopathy causal genes harboring variants such as large deletions or duplication or deep-intronic variants that may have been missed with ES. A study limitation was that even though our inclusion criteria did not have any age restriction for subject recruitment the neuromuscular clinic caters mainly to the adult patients and hence pediatric cases were underrepresented in this study. Though this is a single center study, patients were referred to the center from all over the Indian subcontinent with diverse ethnicities and religious origins. Another limitation of our study was the lack of segregation analysis of compound heterozygous variant combinations identified in patients of our cohort. This is due to difficulty in the current setting in the region based on from where the patients travel and come to clinic and unavailability of parents or children of the patients. Segregation study is needed that will further enhance our understanding of the variant distribution in the population and for better family planning.

The paucity of population-based genetic testing in Indian subcontinent in public databases which may lead to insufficiency of minor allele frequency, lack of reports of similar myopathy patient(s) harboring the variant or unavailable functional data is a limitation in this study. Yet, this also points towards the immediate need and importance of studies such as ours on genetic testing with clinical correlation on large Asian cohorts, either disease-specific or general healthy population.

Finally, to our knowledge, the current study is the first comprehensive clinical-exome sequencing effort on a large genetic myopathy cohort in the Indian subcontinent that has enhanced our understanding of the spectrum of gene-variant-myopathy-subtype landscape in India yielding a high diagnostic rate. In this genomic era, studies such as this in different developing countries and continents on specific disease cohorts with diverse ethnicities will enable enhancement of the repertoire in the global genomic databases such as ExAc (https://exac.broadinstitute.org/), gnomAD (https://gnomad.broadinstitute.org/) and also country-specific large databases such as the UK100,000 Genome project (https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/), NIH All of US Genomics program (https://allofus.nih.gov/) and others for faster and more accurate variant classification, faster enhanced diagnostics, and the understanding of genotype-phenotype correlations.

535	
536	ETHICS STATEMENT
537 538 539 540 541 542	Written, informed consent was obtained from all individuals or minors' parent or legal guardian or next of kin for the publication of any potentially identifiable images or data included in this article. Written informed consents were obtained from all participants of the study for all procedures according to approved Ethics committee Institutional Review Board protocol. All participants (including parents or legal guardians in case of minor patients) were provided pre- and post-test routine genetic counseling.
543	CONFLICT OF INTEREST
544 545 546 547 548	The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Dr. Chakravorty reports grants from Muscular Dystrophy Association, and Jain Foundation, during the conduct of the study. Dr. Hegde reports that she is the VP and CSO of Global Lab Services, PerkinElmer, Inc. that does diagnostic testing and has equity in the company without any conflict of interest.
549	AUTHOR CONTRIBUTIONS
550 551 552 553 554 555	SC and MH had full access to all data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis. SC and MH designed, conceptualized and oversaw the entire study. Acquisition, analysis, or interpretation of data was done by SC, BRRN, SK, MS, AB, RD, PG, LR, and LG. Drafting of the manuscript was done by SC, SK, MS. Critical revision of the manuscript for important intellectual content was done by all authors. Statistical analysis was performed by SC, BRRN, SK, RD, PG, and LR. SC obtained funding. SC, MH and SK supervised the entire study.
556	ACKNOWLDGEMENTS
557	The authors thank the patients and their families for study participation, and the funding sources.
558	FUNDING
559 560 561	This work is supported by the Jain Foundation Focused Research Grant, Muscular Dystrophy Association Grant (MDA578400), and Sanofi-Genzyme Investigator Sponsored Studies Grant (SGZ-2017-11829) to S.C.
562 563	B.R.R.N., and M.H. are employees of Perkin Elmer Genomics. M.H. is also an adjunct professor of Georgia Institute of Technology.
564	
565	
566	SUPPLEMENTARY MATERIAL
567	Supplementary Methods
568	Questionnaires for patient recruitment

Table S1. Clinical symptoms and gene diagnosis of molecularly diagnosed patients

570

571

572

DATA AVAILABILITY STATEMENT

- 573 The original contributions presented in the study are included in the article/supplementary material;
- further inquiries can be directed to the corresponding author/s. This data can be found here:
- 575 https://doi.org/10.5061/dryad.tmpg4f4w6

576 577

577578

579

REFERENCES

- 580 1. Chakravorty S, Berger K, Arafat D, Nallamilli BRR, Subramanian HP, Joseph S, et al.
- Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter
- 582 deletion. Muscle Nerve. 2019;60(1):98-103.
- 583 2. Benarroch L, Bonne G, Rivier F, Hamroun D. The 2020 version of the gene table of
- neuromuscular disorders (nuclear genome). Neuromuscular disorders : NMD. 2019;29(12):980-1018.
- Bonne G, Rivier F, Hamroun D. The 2019 version of the gene table of neuromuscular
- disorders (nuclear genome). Neuromuscular disorders: NMD. 2018;28(12):1031-63.
- 587 4. Bonne G, Rivier F, Hamroun D. The 2018 version of the gene table of monogenic
- neuromuscular disorders (nuclear genome). Neuromuscular disorders: NMD. 2017;27(12):1152-83.
- 589 5. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update.
- 590 Acta Myol. 2014;33(1):1-12.
- 591 6. Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, et al. Genetic
- landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin
- 593 Transl Neurol. 2018;5(12):1574-87.
- 594 7. Guglieri M, Magri F, D'Angelo MG, Prelle A, Morandi L, Rodolico C, et al. Clinical,
- molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle
- muscular dystrophy patients. Human mutation. 2008;29(2):258-66.
- 8. Rahimov F, Kunkel LM. The cell biology of disease: cellular and molecular mechanisms
- underlying muscular dystrophy. J Cell Biol. 2013;201(4):499-510.
- 599 9. Mahmood OA, Jiang XM. Limb-girdle muscular dystrophies: where next after six decades
- 600 from the first proposal (Review). Mol Med Rep. 2014;9(5):1515-32.
- 601 10. Yu M, Zheng Y, Jin S, Gang Q, Wang Q, Yu P, et al. Mutational spectrum of Chinese LGMD
- patients by targeted next-generation sequencing. PLoS One. 2017;12(4):e0175343.
- 603 11. Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, et al. The genetic basis of
- undiagnosed muscular dystrophies and myopathies: Results from 504 patients. Neurology.
- 605 2016;87(1):71-6.

- Reddy HM, Cho KA, Lek M, Estrella E, Valkanas E, Jones MD, et al. The sensitivity of
- exome sequencing in identifying pathogenic mutations for LGMD in the United States. Journal of
- 608 human genetics. 2017;62(2):243-52.
- 609 13. Majumder PP, Basu A. A genomic view of the peopling and population structure of India.
- 610 Cold Spring Harb Perspect Biol. 2014;7(4):a008540.
- 611 14. Majumder PP. The human genetic history of South Asia. Curr Biol. 2010;20(4):R184-7.
- 612 15. Moorjani P, Patterson N, Loh PR, Lipson M, Kisfali P, Melegh BI, et al. Reconstructing
- Roma history from genome-wide data. PLoS One. 2013;8(3):e58633.
- 614 16. Krithika S, Maji S, Vasulu TS. A microsatellite study to disentangle the ambiguity of
- 615 linguistic, geographic, ethnic and genetic influences on tribes of India to get a better clarity of the
- antiquity and peopling of South Asia. Am J Phys Anthropol. 2009;139(4):533-46.
- 17. Jones MA, Bhide S, Chin E, Ng BG, Rhodenizer D, Zhang VW, et al. Targeted polymerase
- chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital
- disorders of glycosylation. Genetics in medicine: official journal of the American College of
- 620 Medical Genetics. 2011;13(11):921-32.
- 621 18. Chakravorty S, Ankala A, Hegde MR. Implementation of Exome Sequencing Assay. In:
- Netto GJ, Kaul KL, editors. Genomic Applications in Pathology. Cham: Springer International
- 623 Publishing; 2019. p. 261-81.
- 624 19. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
- for the interpretation of sequence variants: a joint consensus recommendation of the American
- 626 College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet
- 627 Med. 2015;17(5):405-24.
- 628 20. Fanin M, Nascimbeni AC, Fulizio L, Angelini C. The frequency of limb girdle muscular
- dystrophy 2A in northeastern Italy. Neuromuscular disorders: NMD. 2005;15(3):218-24.
- 630 21. Pathak P, Sharma MC, Sarkar C, Jha P, Suri V, Mohd H, et al. Limb girdle muscular
- dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and
- histopathological correlation. Neurol India. 2010;58(4):549-54.
- 633 22. Wenzel K, Geier C, Qadri F, Hubner N, Schulz H, Erdmann B, et al. Dysfunction of
- dysferlin-deficient hearts. Journal of molecular medicine (Berlin, Germany). 2007;85(11):1203-14.
- 635 23. Choi ER, Park SJ, Choe YH, Ryu DR, Chang SA, Choi JO, et al. Early detection of cardiac
- 636 involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement
- 637 cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:31.
- 638 24. Olivé M, Goldfarb LG, Shatunov A, Fischer D, Ferrer I. Myotilinopathy: refining the clinical
- and myopathological phenotype. Brain: a journal of neurology. 2005;128(Pt 10):2315-26.
- Park YE, Kim HS, Choi ES, Shin JH, Kim SY, Son EH, et al. Limb-girdle phenotype is
- frequent in patients with myopathy associated with GNE mutations. Journal of the neurological
- 642 sciences. 2012;321(1-2):77-81.
- 643 26. Balci B, Uyanik G, Dincer P, Gross C, Willer T, Talim B, et al. An autosomal recessive limb
- 644 girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg
- 645 syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord. 2005;15(4):271-
- 646 5.

- 647 27. Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, et al. Juvenile limb-
- 648 girdle muscular dystrophy: Clinical, histopathological and genetic data from a small community
- living in the Reunion Island. Brain: a journal of neurology. 1996;119(1):295-308.
- 650 28. Khadilkar SV, Nallamilli BRR, Bhutada A, Hegde M, Gandhi K, Faldu HD, et al. A report on
- 651 GNE myopathy: Individuals of Rajasthan ancestry share the Roma gene. Journal of the neurological
- 652 sciences. 2017;375:239-40.
- 653 29. Celeste FV, Vilboux T, Ciccone C, de Dios JK, Malicdan MC, Leoyklang P, et al. Mutation
- update for GNE gene variants associated with GNE myopathy. Hum Mutat. 2014;35(8):915-26.
- 655 30. Chamova T, Guergueltcheva V, Gospodinova M, Krause S, Cirak S, Kaprelyan A, et al. GNE
- myopathy in Roma patients homozygous for the p.I618T founder mutation. Neuromuscul Disord.
- 657 2015;25(9):713-8.
- 658 31. Nalini A, Gayathri N, Nishino I, Hayashi YK. GNE myopathy in India. Neurol India.
- 659 2013;61(4):371-4.
- Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. J
- 661 Neurol Neurosurg Psychiatry. 2015;86(4):385-92.
- 662 33. Argov Z, Mitrani Rosenbaum S. GNE Myopathy: Two Clusters with History and Several
- Founder Mutations. J Neuromuscul Dis. 2015;2(s2):S73-S6.
- 664 34. Vissing J, Barresi R, Witting N, Van Ghelue M, Gammelgaard L, Bindoff LA, et al. A
- heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy.
- 666 Brain. 2016;139(Pt 8):2154-63.
- 667 35. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, et al. Dysferlin, a novel skeletal muscle
- gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet.
- 669 1998;20(1):31-6.
- 670 36. Urtizberea JA, Bassez G, Leturcq F, Nguyen K, Krahn M, Levy N. Dysferlinopathies. Neurol
- 671 India. 2008;56(3):289-97.
- 672 37. Prelle A, Sciacco M, Tancredi L, Fagiolari G, Comi GP, Ciscato P, et al. Clinical,
- 673 morphological and immunological evaluation of six patients with dysferlin deficiency. Acta
- 674 Neuropathol. 2003;105(6):537-42.
- 675 38. Morisaki H, Higuchi I, Abe M, Osame M, Morisaki T. First missense mutations (R388W and
- 676 R425H) of AMPD1 accompanied with myopathy found in a Japanese patient. Hum Mutat.
- 677 2000;16(6):467-72.
- 678 39. Gross M, Rotzer E, Kolle P, Mortier W, Reichmann H, Goebel HH, et al. A G468-T AMPD1
- mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the
- 680 Caucasian population. Neuromuscul Disord. 2002;12(6):558-65.
- Norman B, Glenmark B, Jansson E. Muscle AMP deaminase deficiency in 2% of a healthy
- 682 population. Muscle Nerve. 1995;18(2):239-41.
- 683 41. Verzijl HT, van Engelen BG, Luyten JA, Steenbergen GC, van den Heuvel LP, ter Laak HJ,
- et al. Genetic characteristics of myoadenylate deaminase deficiency. Annals of neurology.
- 685 1998;44(1):140-3.
- Norman B, Mahnke-Zizelman DK, Vallis A, Sabina RL. Genetic and other determinants of
- 687 AMP deaminase activity in healthy adult skeletal muscle. Journal of applied physiology (Bethesda,
- 688 Md: 1985). 1998;85(4):1273-8.

- 689 43. Chakravorty S, Hegde M. Inferring the effect of genomic variation in the new era of
- 690 genomics. Hum Mutat. 2018;39(6):756-73.
- 691 44. Vladutiu GD. Heterozygosity: an expanding role in proteomics. Mol Genet Metab.
- 692 2001;74(1-2):51-63.
- 693 45. de Morrée A, Lutje Hulsik D, Impagliazzo A, van Haagen HHHBM, de Galan P, van
- Remoortere A, et al. Calpain 3 Is a Rapid-Action, Unidirectional Proteolytic Switch Central to
- 695 Muscle Remodeling. PLOS ONE. 2010;5(8):e11940.
- 696 46. Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, et al. Molecular
- diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat. 2004;24(1):52-62.
- 698 47. Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, et al. Analysis of the UK
- 699 diagnostic strategy for limb girdle muscular dystrophy 2A. Brain: a journal of neurology.
- 700 2007;130(Pt 12):3237-49.
- 701 48. Shirafuji T, Otsuka Y, Kobessho H, Minami N, Hayashi Y, Nishino I, et al. [Case of
- 702 LGMD2A (calpainopathy) clinically presenting as Miyoshi distal myopathy]. Rinsho shinkeigaku =
- 703 Clinical neurology. 2008;48(9):651-5.
- 704 49. Sáenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, et al. LGMD2A: genotype-
- 705 phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain: a journal of
- 706 neurology. 2005;128(Pt 4):732-42.
- 707 50. Richard I, Roudaut C, Saenz A, Pogue R, Grimbergen JE, Anderson LV, et al.
- Calpainopathy-a survey of mutations and polymorphisms. Am J Hum Genet. 1999;64(6):1524-40.
- 709 51. Khadilkar SV, Chaudhari CR, Dastur RS, Gaitonde PS, Yadav JG. Limb-girdle muscular
- 710 dystrophy in the Agarwals: Utility of founder mutations in CAPN3 gene. Annals of Indian Academy
- 711 of Neurology. 2016;19(1):108-11.
- 712 52. Ankala A, Kohn JN, Dastur R, Gaitonde P, Khadilkar SV, Hegde MR. Ancestral founder
- 713 mutations in calpain-3 in the Indian Agarwal community: historical, clinical, and molecular
- 714 perspective. Muscle Nerve. 2013;47(6):931-7.
- 715 53. Todorova A, Kress W, Mueller C. Novel mutations in the calpain 3 gene in Germany.
- 716 Clinical genetics. 2005;67(4):356-8.
- 717 54. Nilsson MI, Macneil LG, Kitaoka Y, Alqarni F, Suri R, Akhtar M, et al. Redox state and
- 718 mitochondrial respiratory chain function in skeletal muscle of LGMD2A patients. PLoS One.
- 719 2014;9(7):e102549.
- 720 55. Piluso G, Politano L, Aurino S, Fanin M, Ricci E, Ventriglia VM, et al. Extensive scanning of
- the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet. 2005;42(9):686-
- 722 93.
- 723 56. Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pécheux C, Testard H, et al.
- 724 CAPN3 mutations in patients with idiopathic eosinophilic myositis. Annals of neurology.
- 725 2006;59(6):905-11.
- 726 57. Krahn M, Pécheux C, Chapon F, Béroud C, Drouin-Garraud V, Laforet P, et al.
- 727 Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic
- deletion and evidence for messenger RNA decay. Clinical genetics. 2007;72(6):582-92.

- 729 58. Blázquez L, Azpitarte M, Sáenz A, Goicoechea M, Otaegui D, Ferrer X, et al.
- 730 Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-
- 731 girdle muscular dystrophy 2A diagnosis. Neurogenetics. 2008;9(3):173-82.
- 732 59. Bartoli M, Desvignes JP, Nicolas L, Martin K. Exome sequencing as a second-tier diagnostic
- approach for clinically suspected dysferlinopathy patients. Muscle Nerve. 2014;50(6):1007-10.
- 734 60. Krahn M, Goicoechea M, Hanisch F, Groen E, Bartoli M, Pécheux C, et al. Eosinophilic
- 735 infiltration related to CAPN3 mutations: a pathophysiological component of primary calpainopathy?
- 736 Clinical genetics. 2011;80(4):398-402.
- 737 61. Balci B, Aurino S, Haliloglu G, Talim B, Erdem S, Akcören Z, et al. Calpain-3 mutations in
- 738 Turkey. European journal of pediatrics. 2006;165(5):293-8.
- 739 62. Stehlikova K, Skalova D, Zidkova J, Mrazova L, Vondracek P, Mazanec R, et al. Autosomal
- recessive limb-girdle muscular dystrophies in the Czech Republic. BMC Neurol. 2014;14:154.
- 741 63. Krahn M, Bernard R, Pecheux C, Hammouda el H, Eymard B, Lopez de Munain A, et al.
- Screening of the CAPN3 gene in patients with possible LGMD2A. Clinical genetics. 2006;69(5):444-
- 743 9
- 744 64. Xi J, Blandin G, Lu J, Luo S, Zhu W, Béroud C, et al. Clinical heterogeneity and a high
- proportion of novel mutations in a Chinese cohort of patients with dysferlinopathy. Neurol India.
- 746 2014;62(6):635-9.
- 747 65. Krahn M, Béroud C, Labelle V, Nguyen K, Bernard R, Bassez G, et al. Analysis of the DYSF
- mutational spectrum in a large cohort of patients. Hum Mutat. 2009;30(2):E345-75.
- Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, et al. Genomic organization of the
- dysferlin gene and novel mutations in Miyoshi myopathy. Neurology. 2001;57(2):271-8.
- 751 67. Jin SQ, Yu M, Zhang W, Lyu H, Yuan Y, Wang ZX. Dysferlin Gene Mutation Spectrum in a
- Large Cohort of Chinese Patients with Dysferlinopathy. Chinese medical journal.
- 753 2016;129(19):2287-93.
- Huang Y, Verheesen P, Roussis A, Frankhuizen W, Ginjaar I, Haldane F, et al. Protein
- studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display.
- European journal of human genetics: EJHG. 2005;13(6):721-30.
- 757 69. Rosales XQ, Gastier-Foster JM, Lewis S, Vinod M, Thrush DL, Astbury C, et al. Novel
- diagnostic features of dysferlinopathies. Muscle Nerve. 2010;42(1):14-21.
- 759 70. Nguyen K, Bassez G, Krahn M, Bernard R, Laforêt P, Labelle V, et al. Phenotypic study in
- 760 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol.
- 761 2007;64(8):1176-82.
- 762 71. Vincent AE, Rosa HS, Alston CL, Grady JP, Rygiel KA, Rocha MC, et al. Dysferlin
- mutations and mitochondrial dysfunction. Neuromuscul Disord. 2016;26(11):782-8.
- 764 72. Middel V, Zhou L, Takamiya M, Beil T, Shahid M, Roostalu U, et al. Dysferlin-mediated
- 765 phosphatidylserine sorting engages macrophages in sarcolemma repair. Nature communications.
- 766 2016;7:12875.
- 767 73. Szymanska S, Rokicki D, Karkucinska-Wieckowska A, Szymanska-Debinska T, Ciara E,
- Ploski R, et al. Case report of an adolescent girl with limb-girdle muscular dystrophy type 2B the
- visefulness of muscle protein immunostaining in the diagnosis of dysferlinopathies. Folia
- 770 neuropathologica. 2014;52(4):452-6.

- 771 74. Gallardo E, de Luna N, Diaz-Manera J, Rojas-García R, Gonzalez-Quereda L, Flix B, et al.
- Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the
- diagnosis of dysferlin myopathy. PLoS One. 2011;6(12):e29061.
- 774 75. Turan S, Farruggio AP, Srifa W, Day JW, Calos MP. Precise Correction of Disease Mutations
- in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.
- Molecular therapy: the journal of the American Society of Gene Therapy. 2016;24(4):685-96.
- 777 76. Stehlíková K, Skálová D, Zídková J, Haberlová J, Voháňka S, Mazanec R, et al. Muscular
- dystrophies and myopathies: the spectrum of mutated genes in the Czech Republic. Clinical genetics.
- 779 2017;91(3):463-9.
- 780 77. Klinge L, Aboumousa A, Eagle M, Hudson J, Sarkozy A, Vita G, et al. New aspects on
- patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry.
- 782 2010;81(9):946-53.
- 783 78. Vilchez JJ, Gallano P, Gallardo E, Lasa A, Rojas-García R, Freixas A, et al. Identification of
- a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population.
- 785 Arch Neurol. 2005;62(8):1256-9.
- 786 79. Bean LJ, Tinker SW, da Silva C, Hegde MR. Free the data: one laboratory's approach to
- knowledge-based genomic variant classification and preparation for EMR integration of genomic
- 788 data. Hum Mutat. 2013;34(9):1183-8.
- 789 80. Park YE, Kim HS, Lee CH, Nam TS, Choi YC, Kim DS. Two common mutations
- 790 (p.Gln832X and c.663+1G>C) account for about a third of the DYSF mutations in Korean patients
- with dysferlinopathy. Neuromuscul Disord. 2012;22(6):505-10.
- 792 81. Lo HP, Cooper ST, Evesson FJ, Seto JT, Chiotis M, Tay V, et al. Limb-girdle muscular
- dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord.
- 794 2008;18(1):34-44.
- 795 82. Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, et al. The Clinical
- Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet.
- 797 2016;2(4):e89.
- 798 83. Dastur RS, Gaitonde PS, Kachwala M, Nallamilli BRR, Ankala A, Khadilkar SV, et al.
- 799 Detection of Dysferlin Gene Pathogenic Variants in the Indian Population in Patients Predicted to
- 800 have a Dysferlinopathy Using a Blood-based Monocyte Assay and Clinical Algorithm: A Model for
- Accurate and Cost-effective Diagnosis. Annals of Indian Academy of Neurology. 2017;20(3):302-8.
- 802 84. Dominov JA, Uyan O, McKenna-Yasek D, Nallamilli BRR, Kergourlay V, Bartoli M, et al.
- 803 Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. Ann Clin Transl
- 804 Neurol. 2019;6(4):642-54.
- 805 85. Winckler PB, da Silva AMS, Coimbra-Neto AR, Carvalho E, Cavalcanti EBU, Sobreira CFR,
- et al. Clinicogenetic lessons from 370 patients with autosomal recessive limb-girdle muscular
- 807 dystrophy. Clinical genetics. 2019;96(4):341-53.
- 808 86. Carrillo N, Malicdan MC, Huizing M. GNE Myopathy. In: Adam MP, Ardinger HH, Pagon
- 809 RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews(®). Seattle (WA): University
- 810 of Washington, Seattle
- 811 Copyright © 1993-2020, University of Washington, Seattle. GeneReviews is a registered trademark
- of the University of Washington, Seattle. All rights reserved.; 1993.

- 813 87. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, et al. The UDP-N-
- 814 acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary
- inclusion body myopathy. Nature genetics. 2001;29(1):83-7.
- 816 88. Argov Z, Eisenberg I, Grabov-Nardini G, Sadeh M, Wirguin I, Soffer D, et al. Hereditary
- inclusion body myopathy: the Middle Eastern genetic cluster. Neurology. 2003;60(9):1519-23.
- 818 89. Cho A, Hayashi YK, Monma K, Oya Y, Noguchi S, Nonaka I, et al. Mutation profile of the
- 619 GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy). J
- 820 Neurol Neurosurg Psychiatry. 2014;85(8):914-7.
- 821 90. Chaouch A, Brennan KM, Hudson J, Longman C, McConville J, Morrison PJ, et al. Two
- 822 recurrent mutations are associated with GNE myopathy in the North of Britain. J Neurol Neurosurg
- 823 Psychiatry. 2014;85(12):1359-65.
- 824 91. Cerino M, Gorokhova S, Béhin A, Urtizberea JA, Kergourlay V, Salvo E, et al. Novel
- Pathogenic Variants in a French Cohort Widen the Mutational Spectrum of GNE Myopathy. J
- 826 Neuromuscul Dis. 2015;2(2):131-6.
- 827 92. Saechao C, Valles-Ayoub Y, Esfandiarifard S, Haghighatgoo A, No D, Shook S, et al. Novel
- 828 GNE mutations in hereditary inclusion body myopathy patients of non-Middle Eastern descent.
- 829 Genetic testing and molecular biomarkers. 2010;14(2):157-62.
- 830 93. de Dios JK, Shrader JA, Joe GO, McClean JC, Williams K, Evers R, et al. Atypical
- presentation of GNE myopathy with asymmetric hand weakness. Neuromuscul Disord.
- 832 2014;24(12):1063-7.
- 833 94. Park YE, Kim DS, Choi YC, Shin JH. Progression of GNE Myopathy Based on the Patient-
- Reported Outcome. Journal of clinical neurology (Seoul, Korea). 2019;15(3):275-84.
- 835 95. Chen Y, Xi J, Zhu W, Lin J, Luo S, Yue D, et al. GNE myopathy in Chinese population:
- hotspot and novel mutations. Journal of human genetics. 2019;64(1):11-6.
- 837 96. Zhao J, Wang Z, Hong D, Lv H, Zhang W, Chen J, et al. Mutational spectrum and clinical
- features in 35 unrelated mainland Chinese patients with GNE myopathy. Journal of the neurological
- 839 sciences. 2015;354(1-2):21-6.
- 840 97. No D, Valles-Ayoub Y, Carbajo R, Khokher Z, Sandoval L, Stein B, et al. Novel GNE
- mutations in autosomal recessive hereditary inclusion body myopathy patients. Genetic testing and
- 842 molecular biomarkers. 2013;17(5):376-82.
- 98. Morisaki T, Gross M, Morisaki H, Pongratz D, Zöllner N, Holmes EW. Molecular basis of
- 844 AMP deaminase deficiency in skeletal muscle. Proceedings of the National Academy of Sciences of
- the United States of America. 1992;89(14):6457-61.
- 846 99. Castro-Gago M, Gómez-Lado C, Pérez-Gay L, Eirís-Puñal J, Martínez EP, García-Consuegra
- I, et al. Primary adenosine monophosphate (AMP) deaminase deficiency in a hypotonic infant. J
- 848 Child Neurol. 2011;26(6):734-7.
- 349 100. Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, Brewer C, et al. Individualized iterative
- phenotyping for genome-wide analysis of loss-of-function mutations. Am J Hum Genet.
- 851 2015;96(6):913-25.
- 852 101. Lucioli S, Giusti B, Mercuri E, Vanegas OC, Lucarini L, Pietroni V, et al. Detection of
- common and private mutations in the COL6A1 gene of patients with Bethlem myopathy. Neurology.
- 854 2005;64(11):1931-7.

- Trempe JF, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, et al. Structure of parkin
- reveals mechanisms for ubiquitin ligase activation. Science (New York, NY). 2013;340(6139):1451-
- 857 5
- 858 103. Lamandé SR, Shields KA, Kornberg AJ, Shield LK, Bateman JF. Bethlem myopathy and
- engineered collagen VI triple helical deletions prevent intracellular multimer assembly and protein
- secretion. The Journal of biological chemistry. 1999;274(31):21817-22.
- 861 104. Pan TC, Zhang RZ, Sudano DG, Marie SK, Bönnemann CG, Chu ML. New molecular
- mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the
- 863 COL6A1 gene causes a severe phenotype. Am J Hum Genet. 2003;73(2):355-69.
- 864 105. Baker NL, Mörgelin M, Pace RA, Peat RA, Adams NE, Gardner RJ, et al. Molecular
- consequences of dominant Bethlem myopathy collagen VI mutations. Annals of neurology.
- 866 2007;62(4):390-405.
- 867 106. Fan Y, Liu A, Wei C, Yang H, Chang X, Wang S, et al. Genetic and clinical findings in a
- Chinese cohort of patients with collagen VI-related myopathies. Clinical genetics. 2018;93(6):1159-
- 869 71.
- 870 107. Lampe AK, Dunn DM, von Niederhausern AC, Hamil C, Aoyagi A, Laval SH, et al.
- Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich
- congenital muscular dystrophy and Bethlem myopathy. J Med Genet. 2005;42(2):108-20.
- 873 108. Butterfield RJ, Foley AR, Dastgir J, Asman S, Dunn DM, Zou Y, et al. Position of glycine
- substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and
- mode of inheritance in collagen VI myopathies. Hum Mutat. 2013;34(11):1558-67.
- 876 109. Long CG, Braswell E, Zhu D, Apigo J, Baum J, Brodsky B. Characterization of collagen-like
- peptides containing interruptions in the repeating Gly-X-Y sequence. Biochemistry.
- 878 1993;32(43):11688-95.
- 879 110. Parini R, De Lorenzo P, Dardis A, Burlina A, Cassio A, Cavarzere P, et al. Long term clinical
- history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement
- 881 therapy. Orphanet J Rare Dis. 2018;13(1):32.
- 882 111. Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular
- analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
- Molecular genetics and metabolism reports. 2018;14:3-9.
- 885 112. Pittis MG, Donnarumma M, Montalvo AL, Dominissini S, Kroos M, Rosano C, et al.
- 886 Molecular and functional characterization of eight novel GAA mutations in Italian infants with
- 887 Pompe disease. Hum Mutat. 2008;29(6):E27-36.
- 888 113. Remiche G, Ronchi D, Magri F, Lamperti C, Bordoni A, Moggio M, et al. Extended
- phenotype description and new molecular findings in late onset glycogen storage disease type II: a
- northern Italy population study and review of the literature. Journal of neurology. 2014;261(1):83-97.
- 891 114. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-
- reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons
- learned from 10 years of clinical laboratory testing experience. American journal of medical genetics
- Part C, Seminars in medical genetics. 2012;160c(1):40-9.
- Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al.
- 896 Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the
- genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23(1):47-56.

- 898 116. Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, et al. Pompe disease
- in Austria: clinical, genetic and epidemiological aspects. Journal of neurology. 2018;265(1):159-64.
- 900 117. Turaça LT, de Faria DO, Kyosen SO, Teixeira VD, Motta FL, Pessoa JG, et al. Novel GAA
- mutations in patients with Pompe disease. Gene. 2015;561(1):124-31.
- 902 118. Fu L, Qiu W, Yu Y, Guo Y, Zhao P, Zhang X, et al. Clinical and molecular genetic study of
- 903 infantile-onset Pompe disease in Chinese patients: identification of 6 novel mutations. Gene.
- 904 2014;535(1):53-9.
- 905 119. Beltran Papsdorf TB, Howard JF, Jr., Chahin N. Pearls & Oy-sters: clues to the diagnosis of
- adult-onset acid maltase deficiency. Neurology. 2014;82(9):e73-5.
- 907 120. Bali DS, Tolun AA, Goldstein JL, Dai J, Kishnani PS. Molecular analysis and protein
- processing in late-onset Pompe disease patients with low levels of acid α -glucosidase activity.
- 909 Muscle Nerve. 2011;43(5):665-70.
- 910 121. Liao HC, Chiang CC, Niu DM, Wang CH, Kao SM, Tsai FJ, et al. Detecting multiple
- 911 lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in
- 912 Taiwan. Clinica chimica acta; international journal of clinical chemistry. 2014;431:80-6.
- 913 122. Oliveira J, Santos R, Soares-Silva I, Jorge P, Vieira E, Oliveira ME, et al. LAMA2 gene
- analysis in a cohort of 26 congenital muscular dystrophy patients. Clinical genetics. 2008;74(6):502-
- 915 12.
- 916 123. Rajakulendran S, Parton M, Holton JL, Hanna MG. Clinical and pathological heterogeneity in
- 917 late-onset partial merosin deficiency. Muscle Nerve. 2011;44(4):590-3.
- 918 124. Beytía Mde L, Dekomien G, Hoffjan S, Haug V, Anastasopoulos C, Kirschner J. High
- 919 creatine kinase levels and white matter changes: clinical and genetic spectrum of congenital muscular
- 920 dystrophies with laminin alpha-2 deficiency. Molecular and cellular probes. 2014;28(4):118-22.
- 921 125. Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, et al. The landscape
- of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med.
- 923 2014;16(8):601-8.
- 924 126. Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, et al. Reassessment of
- Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples.
- 926 Genet Med. 2017;19(2):192-203.
- 927 127. Forissier JE, Bonne G, Bouchier C, Duboscq-Bidot L, Richard P, Briault S, et al. [Apical left
- 928 ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation]. Archives
- des maladies du coeur et des vaisseaux. 2005;98(1):67-70.
- 930 128. Hookana E, Junttila MJ, Särkioja T, Sormunen R, Niemelä M, Raatikainen MJ, et al. Cardiac
- arrest and left ventricular fibrosis in a Finnish family with the lamin A/C mutation. Journal of
- 932 cardiovascular electrophysiology. 2008;19(7):743-7.
- 933 129. Forissier JF, Bonne G, Bouchier C, Duboscq-Bidot L, Richard P, Wisnewski C, et al. Apical
- left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. European
- 935 journal of heart failure. 2003;5(6):821-5.
- 936 130. Lakdawala NK, Funke BH, Baxter S, Cirino AL, Roberts AE, Judge DP, et al. Genetic testing
- 937 for dilated cardiomyopathy in clinical practice. Journal of cardiac failure. 2012;18(4):296-303.

- 938 131. Dialynas G, Flannery KM, Zirbel LN, Nagy PL, Mathews KD, Moore SA, et al. LMNA
- variants cause cytoplasmic distribution of nuclear pore proteins in Drosophila and human muscle.
- 940 Hum Mol Genet. 2012;21(7):1544-56.
- 941 132. Dittmer TA, Sahni N, Kubben N, Hill DE, Vidal M, Burgess RC, et al. Systematic
- identification of pathological lamin A interactors. Molecular biology of the cell. 2014;25(9):1493-
- 943 510.
- 944 133. Benedetti S, Menditto I, Degano M, Rodolico C, Merlini L, D'Amico A, et al. Phenotypic
- clustering of lamin A/C mutations in neuromuscular patients. Neurology. 2007;69(12):1285-92.
- 946 134. Pasqualin LM, Reed UC, Costa TV, Quedas E, Albuquerque MA, Resende MB, et al.
- Congenital muscular dystrophy with dropped head linked to the LMNA gene in a Brazilian cohort.
- 948 Pediatric neurology. 2014;50(4):400-6.
- 949 135. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v.2.0:
- 950 the next generation in gene variant databases. Hum Mutat. 2011;32(5):557-63.
- 951 136. Quijano-Roy S, Mbieleu B, Bönnemann CG, Jeannet PY, Colomer J, Clarke NF, et al. De
- novo LMNA mutations cause a new form of congenital muscular dystrophy. Annals of neurology.
- 953 2008;64(2):177-86.
- 954 137. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, et al. Refining genotype-
- 955 phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain:
- 956 a journal of neurology. 2007;130(10):2725-35.
- 957 138. Carrié A, Piccolo F, Leturcq F, de Toma C, Azibi K, Beldjord C, et al. Mutational diversity
- and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D).
- 959 J Med Genet. 1997;34(6):470-5.
- 960 139. van der Kooi AJ, Frankhuizen WS, Barth PG, Howeler CJ, Padberg GW, Spaans F, et al.
- Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families.
- 962 Neurology. 2007;68(24):2125-8.
- 963 140. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan
- genes in patients with myopathy. The New England journal of medicine. 1997;336(9):618-24.
- 965 141. Khadilkar SV, Singh RK, Hegde M, Urtizberea A, Love DR, Chong B. Spectrum of
- mutations in sarcoglycan genes in the Mumbai region of western India: high prevalence of 525del T.
- 967 Neurol India. 2009;57(4):406-10.
- 968 142. Duggan DJ, Manchester D, Stears KP, Mathews DJ, Hart C, Hoffman EP. Mutations in the
- delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy
- 970 (LGMD2). Neurogenetics. 1997;1(1):49-58.
- 971 143. Barresi R, Morris C, Hudson J, Curtis E, Pickthall C, Bushby K, et al. Conserved expression
- of truncated telethonin in a patient with limb-girdle muscular dystrophy 2G. Neuromuscul Disord.
- 973 2015;25(4):349-52.
- 974 144. Ruggieri A, Brancati F, Zanotti S, Maggi L, Pasanisi MB, Saredi S, et al. Complete loss of the
- 975 DNAJB6 G/F domain and novel missense mutations cause distal-onset DNAJB6 myopathy. Acta
- 976 neuropathologica communications. 2015;3:44.
- 977 145. Huizing M, Rakocevic G, Sparks SE, Mamali I, Shatunov A, Goldfarb L, et al.
- Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations.
- 979 Mol Genet Metab. 2004;81(3):196-202.

- 980 146. Weihl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, et al. Targeted sequencing and
- 981 identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord.
- 982 2015;25(4):289-96.
- 983 147. Krause S, Aleo A, Hinderlich S, Merlini L, Tournev I, Walter MC, et al. GNE protein
- expression and subcellular distribution are unaltered in HIBM. Neurology. 2007;69(7):655-9.
- 985 148. Penner J, Mantey LR, Elgavish S, Ghaderi D, Cirak S, Berger M, et al. Influence of UDP-
- 986 GlcNAc 2-epimerase/ManNAc kinase mutant proteins on hereditary inclusion body myopathy.
- 987 Biochemistry. 2006;45(9):2968-77.
- 988 149. Deconinck N, Richard P, Allamand V, Behin A, Lafôret P, Ferreiro A, et al. Bethlem
- 989 myopathy: long-term follow-up identifies COL6 mutations predicting severe clinical evolution. J
- 990 Neurol Neurosurg Psychiatry. 2015;86(12):1337-46.
- 991 150. Deconinck N, Dion E, Ben Yaou R, Ferreiro A, Eymard B, Briñas L, et al. Differentiating
- 992 Emery-Dreifuss muscular dystrophy and collagen VI-related myopathies using a specific CT scanner
- 993 pattern. Neuromuscul Disord. 2010;20(8):517-23.
- 994 151. Martoni E, Urciuolo A, Sabatelli P, Fabris M, Bovolenta M, Neri M, et al. Identification and
- characterization of novel collagen VI non-canonical splicing mutations causing Ullrich congenital
- 996 muscular dystrophy. Hum Mutat. 2009;30(5):E662-72.
- 997 152. Foley AR, Hu Y, Zou Y, Yang M, Medne L, Leach M, et al. Large genomic deletions: a
- 998 novel cause of Ullrich congenital muscular dystrophy. Annals of neurology. 2011;69(1):206-11.
- 999 153. Briñas L, Richard P, Quijano-Roy S, Gartioux C, Ledeuil C, Lacène E, et al. Early onset
- 1000 collagen VI myopathies: Genetic and clinical correlations. Annals of neurology. 2010;68(4):511-20.
- 1001 154. Cui H, Wang J, Zhang C, Wu G, Zhu C, Tang B, et al. Mutation profile of FLNC gene and its
- prognostic relevance in patients with hypertrophic cardiomyopathy. Molecular genetics & genomic
- 1003 medicine. 2018;6(6):1104-13.

1004

1005

1006

1007

1008

1009 **FIGURES**




FIGURE 1. Molecular diagnosis with different genetic myopathy subtypes. Molecular diagnosis using exome sequencing has been established in 49% of the patients with the majority having pathogenic variants identified in one of the following genes *GNE* (31%), *DYSF* (27%), *CAPN3* (19%), indicating that these genes are likely the major contributors to genetic myopathy-like phenotype.




FIGURE 2. Unique pathogenic variants and percent homozygosity identified in major myopathy genes. A) Number of unique pathogenic variants identified in major myopathy genes. B) The percentage of homozygosity observed in the major myopathy subtypes. Among the 3 major myopathy subtypes, 96% of the limb-girdle muscular dystrophy R2 (LGMDR2) patients caused by variants in *DYSF* gene were identified with homozygous variants. C) Mutation spectrum of *CAPN3* gene: *CAPN3* variants identified in the current study are distributed throughout the gene. There is no specific mutation hot spot region but 3 variants are located in exon 10 indicating it as more unstable region prone to genetic variation. D) Two common variants in *GNE* gene: The two common variants in *GNE* gene were detected in exome sequencing with high confidence and also further confirmed by Sanger sequencing. Left side panel indicates the variants confirmation by exome sequencing. Right side panel indicates the variants confirmation by Sanger sequencing.



FIGURE 3. Classical features of common subtypes identified. GNE myopathy (A to C): Tibialis anterior (TA) muscle wasting, normal quadriceps and first dorsal interossei (FDI) muscle wasting identified respectively. Dysferlinopathy (D, E): Gastrocnemius wasting and biceps lump. Calpainopathy (F, G): Scapular winging and ankle contracture. Sarcoglycanopathy (H): Calf hypertrophy. Collagenopathy (I to K): Long finger flexor and ankle contractures.

anterior, Hip adductors,

	iliopsoas, hamstrings and tibialis anterior												
16	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.1319G>A (p.R440Q)	Pathogenic	Pathogenic	(45-48)	c.1319G>A (p.R440Q)	Pathogenic	Pathogenic	(45-48)	F	7000	P
18	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.1642delC (p.Arg548AlafsX47)	Pathogenic	Likely Pathogenic	(59)	c.2051-1G>T	Pathogenic	Pathogenic	(49-52)	F	3877	P
19	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2051-1G>T	Pathogenic	Pathogenic	(49-52)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	M	2503	P
20	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	M	2590	P
21	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2051-1G>T	Pathogenic	Pathogenic	(49-52)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	F	3571	P+AXIA L
22	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	F	2029	P
23	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2050+1G>A	Pathogenic	Pathogenic	(49, 50)	c.2050+1G>A	Pathogenic	Pathogenic	(49, 50)	M	855	P
24	Calpainopathy-specific features: Soleus and Medial	CAPN3	c.2051-1G>T	Pathogenic	Pathogenic	(49-52)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	M	2300	P

	Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	(NM_000070.2)											
25	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c1296_1299delTG (frameshift)	Pathogenic	Not found	Not found	c.2092C>T (p.R698C)	Pathogenic	Pathogenic	(49, 60- 63)	M	5507	P+D
26	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	M	1100	P
27	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	c.2051-1G>T	Pathogenic	Pathogenic	(49-52)	F	4600	P
29	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendoachilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	c.2338G>C (p.D780H)	Pathogenic	Pathogenic	(51-54)	M	5400	D
40	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	M	8795	P
41	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	M	1338 8	P
43	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait,	DYSF (NM_003494.3)	c.4674_4687delAGATCCATCTG TGA (frameshift)	Pathogenic	Not found	Not found	c.4674_4687delAGATCCATCTG TGA (frameshift)	Pathogenic	Not found	Not found	F	4250	P

	wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps												
44	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	F	9065	P
45	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.206T>G (p.V69G)	Pathogenic	Likely Pathogenic	Not found	c.206T>G (p.V69G)	Pathogenic	Likely Pathogenic	Not found	M	3200	P
46	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.6124C>T (p.R2042C)	Pathogenic	Pathogenic/Likely Pathogenic	(69-74)	c.6124C>T (p.R2042C)	Pathogenic	Pathogenic/Likely Pathogenic	(69-74)	M	3707	P
47	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3517dupT (p.Ser1173fs)	Pathogenic	Pathogenic	(65, 75- 77)	c.5713C>T (p.R1905X)	Pathogenic	Pathogenic	(78)	M	NA	P+D
48	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.4060_4062delTCC (p.S1354del)	Pathogenic	VUS	(79)	c.4060_4062delTCC	Pathogenic	VUS	(79)	F	1760	P
49	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	F	2174	P
50	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	F	6390	P+D

51	Dysferlinopathy-specific	DYSF	c.1129C>T (p.R377X)	Pathogenic	Pathogenic/Likely	(80)	c.1129C>T (p.R377X)	Pathogenic	Pathogenic/Likely	(80)	F	5400 P
	features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	(NM_003494.3)			Pathogenic				Pathogenic			
52	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.6124C>T (p.R2042C)	Pathogenic	Pathogenic/Likely Pathogenic	(69-74)	c.6124C>T (p.R2042C)	Pathogenic	Pathogenic/Likely Pathogenic	(69-74)	M	4670 D
54	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	M	5048 P
55	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.796_797delCT (p.Leu298fs)	Pathogenic	Pathogenic	(67, 81, 82)	c.796_797delCT (p.Leu298fs)	Pathogenic	Pathogenic	(67, 81, 82)	F	2679 P+AXIA L
56	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	F	2970 P
57	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	F	1911 D
59	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	M	7865 P+D
60	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood	DYSF (NM_003494.3)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	M	5000 P

	monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps												
61	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.206T>G	Pathogenic	Likely Pathogenic	Not found	c.206T>G	Pathogenic	Likely Pathogenic	Not found	M	2614	P
62	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	F	8000	P
63	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	F	3529	P
64	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	M	2285 5	P
65	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	c.5668-824C>T (p.Asp1890Glyfs*47)	Pathogenic	Pathogenic	(83, 84)	F	1014 6	P+D
66	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.6124C>T (p.R2042C)	Pathogenic	Pathogenic/Likely Pathogenic	(69-74)	c.6124C>T (p.R2042C)	Pathogenic	Pathogenic/Likely Pathogenic	(69-74)	M	4225	P+D
67	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip	DYSF (NM_003494.3)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	c.3137G>A (p.R1046H)	Pathogenic	Pathogenic/Likely Pathogenic	(64-67)	M	2000	P+D

	adductors, hamstrings and quadriceps												
68	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3280T>C (p.W1094R)	Likely Pathogenic	Not found	(85)	c.3280T>C (p.W1094R)	Likely Pathogenic	Not found	(85)	M	1018	P
69	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	c.3041A>G (p.Y1014C)	Pathogenic	Pathogenic/Likely Pathogenic	(68, 69)	M	2674 0	P
74	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Benign/Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1664C>T (p.A524V)	Pathogenic	Pathogenic/Likely Pathogenic	(28, 30, 86)	F	220	D+P
75	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	1309	D+P
76	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	321	D
78	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1664C>T (p.A524V)	Pathogenic	Pathogenic/Likely Pathogenic	(28, 30, 86)	M	1334	D+P
80	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.986T>C (p.I298T)	Pathogenic	Likely Pathogenic	(89, 91, 92)	F	809	D+P
82	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1664C>T (p.A524V)	Pathogenic	Pathogenic/Likely Pathogenic	(28, 30, 86)	M	391	D+P

84	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.478C>T (p.R160X)	Pathogenic	Likely Pathogenic	(29, 93)	M	408	D+P
85	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	587	D+P
86	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.830G>A (p.R246Q)	Pathogenic	Likely Pathogenic	(28, 89, 91, 94- 96)	c.830G>A (p.R246Q)	Pathogenic	Likely Pathogenic	(28, 89, 91, 94- 96)	F	384	D+P
87	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.986T>C (p.I298T)	Pathogenic	Likely Pathogenic	(89, 91, 92)	F	242	D+P
88	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	1986	D+P
89	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.397_398dupAT (p.Glu134fs) (frameshift)	Pathogenic	Pathogenic	Not found	F	245	D+P
90	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	F	209	D+P
91	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	391	D+P
92	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most- affected muscles: Tibialis	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	F	102	D+P

	anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles												
93	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.2189C>T (p.S699L)	Likely Pathogenic	VUS	(97)	F	204	D+P
94	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	144	D+P
95	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	486	D+P
96	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	221	D+P
97	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	152	D+P
98	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.478C>T (p.R160X)	Pathogenic	Likely Pathogenic	(29, 93)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	304	D+P
99	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.816_820delCTCAT (frameshift)	Likely Pathogenic	Not found	Not found	M	367	D+P
100	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1664C>T (p.A524V)	Pathogenic	Pathogenic/Likely Pathogenic	(28, 30, 86)	F	120	D+P

101	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	F	598	D+P
102	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	M	431	D+P
103	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	287	D+P
104	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	c.268C>T (p.R90X)	Pathogenic	Pathogenic	Not found	M	293	D+P
105	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.97G>T (p.E33X)	Pathogenic	Pathogenic/Likely Pathogenic	Not found	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	307	D+P
106	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.925_927delinsTTGGGAT (frameshift)	Likely Pathogenic	Not found	Not found	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	282	D+P
107	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.816_820delCTCAT (frameshift)	Likely Pathogenic	Not found	Not found	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	M	540	D+P
108	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Mostaffected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227. 3)	c.1853T>C (p.I587T)	Pathogenic	Pathogenic/Likely Pathogenic	(29, 89- 91)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathoge nic	(1, 86-88)	F	207	D+P

P: Proximal muscles; D: Distal muscles; M: Male; F: Female

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

Patient No	Clinical/Pathological/Functional Evidence for specific Myopathy Subtype and Variant Classification (Clinical Correlation)	Gene	Variant 1	Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence)	ClinVar Classification	Reported in Published Literature	Variant 2	Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence)	ClinVar Classification	Reported in Published Literature	Gender	CK Level	Muscle weakness
1/6	Most prominent clinical marker: LGMD variable features: mild to severe (wheelchair-bound) of both proximal and distal muscles, and dilated cardiomyopathy	AMPD1 (NM_000036.2)	c.242C>T (p.P81L)	Likely Pathogenic	Likely Benign/Pseudodeficiency	(98)	c.133C>T (p.Q45X)	Pathogenic	VUS	(98, 99)	M	73	P+D
2	Most prominent clinical marker: LGMD variable features: mild to severe (wheelchair-bound) of both proximal and distal muscles, and dilated cardiomyopathy	AMPD1 (NM_000036.2)	c.959A>T (p.K320I)	Likely Pathogenic	Likely Pathogenic/VUS	Not found	c.104delC (p.Pro35Leufs*87)	Likely Pathogenic	Benign	(100)	M	665	P
3	Anoctaminopathy-features: Long periods of Myalgias and difficulty running; Important clinical marker: Asymmetric wasting of calves; Most-affected muscles: Gastrocnemius	ANO5 (NM_213599.2)	c.1406G>A (p.W469X)	Pathogenic	Pathogenic	Not found	c.1406G>A (p.W469X)	Pathogenic	Pathogenic	Not found	M	4100	D
4	Anoctaminopathy-features: Long periods of Myalgias and difficulty running; Important clinical marker: Asymmetric wasting of calves; Most-affected muscles: Gastrocnemius	ANO5 (NM_213599.2)	c.2141_2144dupCTCA (frameshift)	Likely Pathogenic	Not found	Not found	c.2141_2144dupCTCA (frameshift)	Likely Pathogenic	Not found	Not found	M	1626	D
5	Anoctaminopathy-features: Long periods of Myalgias and difficulty running; Important clinical marker: Asymmetric wasting of calves; Most-affected muscles: Gastrocnemius		c.1406G>A (p.W469X)	Pathogenic	Pathogenic	Not found	c.1406G>A (p.W469X)	Pathogenic	Pathogenic	Not found	M	4000	D
31	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendoachilis contractures; Mostaffected muscles: Hip extensors and adductors, ankle dorsiflexors.	COL6A1 (NM_001848.2)	c.2821_2833del (frameshift)	Likely Pathogenic	Not found	Not found	c.2821_2833del (frameshift)	Likely Pathogenic	Not found	Not found	M	1056	P
32	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendoachilis contractures; Mostaffected muscles: Hip extensors and adductors, ankle dorsiflexors.	COL6A1 (NM_001848.2)	c.1056+1G>A	Pathogenic	Pathogenic	(101-105)					M	212	P
35	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendoachilis contractures; Mostaffected muscles: Hip extensors and adductors, ankle dorsiflexors.	COL6A2 (NM_001849.3)	c.857G>A (G286E)	Pathogenic	Pathogenic/Likely Pathogenic	(106-109)	_				M	152	P+D
71	Emery-Dreifuss muscular- dystrophy features: Tripping and toe walking, Winging of scapula, wrist and ankle contractures; Most-affected muscles: Biceps brachii, ankle dorsiflexors	EMD (NM_000117.2)	c.680delG (frameshift)	Likely Pathogenic	Not found	Not found	-				M	791	P
72	Later-Onset Pompe Disease (LOPD) features: Difficulty getting up from ground followed by breathing difficulty, Respiratory muscles weakness; Most-affected muscles: Hip extensors and respiratory muscles	GAA (NM_000152.5)	c.1A>G (p.M1V)	Pathogenic	Pathogenic/Likely Pathogenic	(110-116)	c.1831G>A (p.G611S)	Likely Pathogenic	VUS	(114, 117, 118)	F	1197	P+D
73	-	GAA (NM_000152.5)	c.1841C>T (p.T614M)	Likely Pathogenic	VUS	(12, 119- 121)	c.1841C>T (p.T614M)	Likely Pathogenic	VUS	(12, 119- 121)	M	1141	P
109	Merosin-deficiency-congenital-muscular-dystrophy-type 1 features: Difficulty getting up from ground; Winging of scapula, calf hypertrophy; Mild upper and lower girdle weakness.	LAMA2 (NM_000426.3)	c.2749+1G>C	Pathogenic	Pathogenic	(122-124)	c.2749+1G>C	Pathogenic	Pathogenic	(122-124)	M	9083	P

37	Laminopathy features: Difficulty getting up from ground; Muscles most affected: Iliopsoas, hip adductors, hamstrings and quadriceps	LMNA (NM_170707.4)	c.1621C>T (p.R541C)	Pathogenic	Pathogenic/Likely Pathogenic	(125-132)	-				F	1234	P
38	Laminopathy features: Difficulty getting up from ground; Muscles most affected: Iliopsoas, hip adductors, hamstrings and quadriceps. Cardiac involvement: Atrioventricular conduction blocks.	<i>LMNA</i> (NM_170707.4)	c.116A>G (p.N39S)	Pathogenic	Pathogenic	(133-136)	_				F	-	P
39	Laminopathy features: Difficulty getting up from ground; Muscles most affected: Iliopsoas, hip adductors, hamstrings and quadriceps	LMNA (NM_170707.3)	c.116A>AG (p.N39S)	Pathogenic	Pathogenic	(133-136)	-				M	91	P
110	POMT1-proteinopathy-features: Difficulty getting up from ground, Winging of scapula, calf hypertrophy; Most-affected muscle-weakness: Mild upper and lower girdle weakness	POMT1 (NM_007171.3)	c.1868G>C (p.R623T)	Pathogenic	Not found	(137)	c.1868G>C (p.R623T)	Pathogenic	Not found	(137)	F	2261	P
111	Sarcoglycanopathy features: Absent alpha sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCA (NM_000023.4)	c.157+1G>A	Pathogenic	Likely Pathogenic	(138, 139)	c.157+1G>A	Pathogenic	Likely Pathogenic	(138, 139)	F	-	P
112	Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCB (NM_000232.4)	c.346A>G (p.M116V)	Likely Pathogenic	VUS	(6)	c.346A>G (p.M116V)	Likely Pathogenic	VUS	(6)	M	7646	P
114	Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCB (NM_000232.4)	c.544A>C (p.T182P)	Likely Pathogenic	VUS	(140)	c.544A>C (p.T182P)	Likely Pathogenic	VUS	(140)	F	15573	P
124	Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCD (NM_000337.5)	c.493C>T (p. R165X)	Pathogenic	Pathogenic	(141, 142)	c.493C>T	c.493C>T (p. R165X)	Pathogenic	Pathogenic	F	8224	P+D
116	Sarcoglycanopathy features: Absent gamma sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCG (NM_000231.2)	c.92G>A (p.W31X)	Likely Pathogenic	Not found	Not found	c.92G>A (p.W31X)	Likely Pathogenic	Not found	Not found	F	13500	P+D
118	Myotilinopathy features: Difficulty getting up from ground, Winging of scapula; Most- affected muscles: Severe upper and lower girdle weakness	MYOT (NM_006790.2)	c.1423C>T (p.Q475X)	Likely Pathogenic	Not found	Not found	-				M	-	P
121	Telethoninopathy features: Tripping on small objects, Foot- drop with weak quadriceps and scapular-winging; Most-affected muscles: Knee extensors and ankle dorsiflexors	TCAP (NM_003673.3)	c.14_15delAG (frameshift)	Likely Pathogenic	Not found	Not found	c.14_15delAG (frameshift)	Likely Pathogenic	Not found	Not found	M	619	P
122	Telethoninopathy features: Tripping on small objects, Foot- drop with weak quadriceps and scapular-winging; Most-affected muscles: Knee extensors and ankle dorsiflexors	TCAP (NM_003673.3)	c.244C>T (p.Gln82X)	Likely Pathogenic	Not found	(143)	c.244C>T (p.Gln82X)	Likely Pathogenic	Not found	(143)	F	854	D
123	LGMDD1 DNAJB6-related / HSP40-proteinopathy features: Difficulty getting up from ground; Difficulty walking on heels; Muscle most-affected: Hip	DNAJB6 (NM_058246.4)	c.273C>G (p.F91L)	Pathogenic	Pathogenic	(144)	-				F	392	P+D

adductors, iliopsoas, gluteus maximus and gastrocnemius

P: Proximal muscles; **D:** Distal muscles; **M**: Male; **F**: Female

Table 4: Clinical features of uncommon subtypes

Parameters	LGMDR3-R6 (Sarcoglycanopathy)	Collagenopathy(LGMD R22 or LGMD D5; COL6A1/A2/A3)	LGMDR12 (Anoctaminopathy)	LGMDR7 (Telethoninopathy)	Pompe Disease	EDMD2 (LMNA- Laminopathy)	MMDD (AMPD1- Myopathy due to monoadenylate deaminase deficiency)	Myofibrillar Myopathy (MYOT- myotilinopathy)	LGMDD1 (DNAJB6, HSP40- proteinopathy)	EDMD1 (EMD- Emery- Dreifuss muscular- dystrophy- X-linked)	LGMDR11 (POMT1- proteinopathy).	LGMD R23 or MDC1A (LAMA2: Merosin- deficiency- congenital- muscular- dystrophy- type 1)
Number of patients	7	7	3	2	2	3	2	1	1	1	1	1
Most Common Presenting symptom	Difficulty getting up from ground and climbing stairs.	Difficulty getting up from ground and toe walking.	Long periods of Myalgias and difficulty running	Tripping on small objects	Difficulty getting up from ground followed by breathing difficulty	Difficulty getting up from ground	Heterogeneous, LGMD features of mild to severe (wheelchair- bound) of both proximal and distal muscles	Difficulty getting up from ground	Difficulty getting up from ground	Tripping and toe walking	Difficulty getting up from ground	Difficulty getting up from ground
Muscles most affected	Hip and knee extensors, ankle dorsiflexors	Hip extensors and adductors,ankle dorsiflexors	Gastrocnemius	Knee extensors and ankle dorsiflexors	Hip extensors and respiratory muscles	Iliopsoas, hip adductors, hamstrings and quadriceps	Both proximal and distal muscle, presentation very heterogeneous	Severe upper and lower girdle weakness	Hip adductors, iliopsoas, gluteus maximus and gastrocnemius	Biceps brachii, ankle dorsiflexors	Mild upper and lower girdle weakness	Mild upper and lower girdle weakness
Important clinical markers	Calf hypertrophy	Finger flexors and tendo- achilis contractures	Asymmetric wasting of calves	Foot-drop with weak quadriceps and scapularwinging.	Respiratory muscles weakness	-	LGMD variable features, dilated cardiomyopathy	Winging of scapula	Difficulty walking on heels	Winging of scapula, wrist and ankle contractures	Winging of scapula, calf hypertrophy	Winging of scapula, calf hypertrophy
CPK levels(Range)	6800-15573 IU/L	152-5467 IU/L.	1626-4100 IU/L	854 and 619 IU/L	1141 and 1197 IU/L	91-1234U/L	73 IU/L (normal) to 665 IU/L (mild elevation)	1100 IU/L	392 IU/L	791 IU/L	2261 IU/L	9083 IU/L

1135 Table 5: Clinical symptoms and genotype of patients with pathogenic variants in more than one gene.

Patient No.	Gender	Gene	Variant	Zygosity	Classification	CK Level (IU/L)	Muscle Weakness: Proximal (P)/Distal (D)	Muscle Biopsy Result	Ambulation Status (a= ambulatory)	Cardiac Involvement
118	Male	GNE	c.2179G>A (p.V727M)	Heterozygous	Pathogenic	NA	P+D	NA	a	No
		GNE	c.827T>G (p.F276C)	Heterozygous	Likely Pathogenic					
		MYOT	c.1423C>T (p.Q475X)	Heterozygous	Pathogenic					
42	Female	DYSF	c.206T>G (p.V69G)	Heterozygous	Pathogenic	10500	P	myopathy	a	No

		DYSF	c.1397+2_1397+3insT	Heterozygous	Likely Pathogenic						1136
		SIL1	c.274C>T (p.R92W)	Heterozygous							1137
		GAA	c.2725G>A (p.V909M)	Heterozygous							1138
		GNE	c.2179G>A (p.V727M)	Heterozygous							1139
		GNE GNE	c.986T>C (p.1298T)	Heterozygous							1140
		LAMA2	c.5074G>C (p.V1692L)	Heterozygous							1141
		PLEC	c.5796G>C (p.E1932D)	Heterozygous							1142
110	Female		·-			2261	P	myonothy		N.T	1143
110	remale		c.1868G>C (p.R623T)	Homozygous	_	2201	r	myopathy	a		1144
0.5	N f - 1 -	CAPN3	c.1099G>A (p.G367S)	Heterozygous		507	D	(1-f(TA -ff4-1)			1145
85	Male	CHAT	c.2222G>A (p.R741K)	Heterozygous		587	P	myopathy (left TA affected)	a		1146
			c.753_754delCT (FS)		Likely Pathogenic						1147
		DES	c.897+4_897+5delGG	Heterozygous							1148 1149
		GNE	c.1853T>C (p.1587T)	Homozygous							1149
		NEB	c.14986G>A (p.G4996R)	Heterozygous							1150
		PLEC	c.5524C>T (p.R1842W)	Heterozygous							1152
71	Male	EMD	c.680delG (FS)		Likely Pathogenic	791	P	NA	a	INIO	1153
		PLEC	c.5447_5459delTGGAGGCCGAGGC (FS)		Likely Pathogenic						1154
		MYH2	c.3622G>A (p.E1208K)	Heterozygous	VUS						1155
112	Male	FKRP	c.493C>T (p.P165S)	Heterozygous	VUS	7646	P	NA	a		1156
		GAA	c.794G>A (p.S265N)	Heterozygous	Likely Pathogenic						1157
		SGCB	c.346A>G (p.M116V)	Homozygous	Likely Pathogenic						1158
		SGCD	c.68A>G (p.Y23C)	Heterozygous	VUS						1159
		AMPD1	c.317A>G (p.K106R)	Heterozygous	VUS						1160
1 or 6	Male	CAPN3	c.1793_1796delAAAC (FS)	Homozygous	Likely Pathogenic	3561	P	no diagnosis	a	NO	1161
		AMPD1	c.242C>T (p.P81L)	Heterozygous	Likely Pathogenic						1162
		AMPD1	c.133C>T (p.Q45X)	Heterozygous	Pathogenic						1163 1164
39	Male	DOK7	c.601C>T (p.R201X)	Heterozygous	Pathogenic	91	P	NA	a	Nia	1165
		DMD	c.932A>G (p.D311G)	Heterozygous							1166
		<i>LMNA</i>	c.116A>G (p.N39S)	Heterozygous							1167
47	Male	DYSF	c.5713C>T (p.Arg1905Ter)	Heterozygous		Not known	P+D	dystrophy + inflammation	a		1168
		DYSF	c.3517dupT (p.Ser1173Phefs)	Heterozygous				7 1 7			1169
		MYH2	c.4537+1G>A	Heterozygous	-						1170
50	Female		c.3041A>G (p.Y1014C)	Homozygous		6390	P+D	Absence of Dysferlin staining	a	NA	1171
	1 01110110	2101	(Filleria)	11011102/8000	1 44110 801110	0000	1.2	1 20001100 01 2 3 01011111 0111111119			1172
		11105	140CC A / WI4COV)	TT 4	D.d.						1173
1 2	Mala	ANO5 CAPN3	c.1406G>A (p.W469X)	Heterozygous	Pathogenic	055	P	NT A			1174
23	Male	CAPNS	c.2050+1G>A	Homozygous	Dathagania	855	P	NA	a		1175
		LIMS2	c.893G>A (p.Trp298X)	Homozygous							1176
5.4	Male	LIMINA	0.075071 (p.11p270A)	Homozygous	i amogenie	22855	P	NA	9		1177
64	iviaie	DYSF	c.5668-824C>T	Homozygous	Pathogenic	44033	1	INA	a		1178
			c.5766delC (FS)	Heterozygous	_						1179 1180
125	Male	GNE	c.2179G>A (p.V727M)	Heterozygous	•	762	P	NA	a		1180
143	iviaie	LMNA	c.706delG (p.Glu236fs)	Heterozygous		102	1	IVA	a		1181
		LIVIIVA	c./oddeto (p.otd23018)	Helefozygous	1 amogenic						1183

Abbreviations

FS Frameshift

Ter Termination of translation **VUS** Variant of Uncertain Significance

CK Serum Creatine Kinase

P Proximal muscle weakness

D Distal muscle weakness

a Ambulatory

TA Tibialis anterior muscle **IU/L** international units per liter

Table 6. Molecular and Clinical aspects of patients (not included in diagnostic yield) with Variants of Uncertain Significance (VUSs) or Likely Pathogenic but with Clinical Correlation with Gene of interest

Patient No	Clinical/Pathological/Functional Evidence for specific Myopathy Subtype and Variant Classification (Clinical Correlation)	Gene	Variant 1	Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence))	ClinVar Classification	Reported in Literature	Variant 2	Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence)	ClinVar Classification	Published Literature Evidence	Gender	CK Level	Muscle weakness
9	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.1298_1299delTG (p.Val433fs)	Pathogenic	Pathogenic/Likely Pathogenic	(53)	c.1745+2T>G	VUS/Likely Pathogenic	Not found	Not found	F	5440	P+D
10	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.430C>T (p.L144F)	VUS/Likely Pathogenic	Not found	Not found	c.430C>T (p.L144F)	VUS/Likely Pathogenic	Not found	Not found	F	NA	P
11	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.439C>T (p.R147X)	Pathogenic	Pathogenic	Not found	c.1543G>A (p.G515R)	VUS/Likely Pathogenic	VUS	Not found	M	1786	P

<u> </u>													
17	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.380-2A>G	VUS/Likely Pathogenic	Not found	Not found	c.380-2A>G	VUS/Likely Pathogenic	Not found	Not found	M	4686	P
28	Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior	CAPN3 (NM_000070.2)	c.1347C>A	VUS/Likely Pathogenic	Not found	Not found	c.1347C>A	VUS/Likely Pathogenic	Not found	Not found	F	4226	P
42	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.206T>G (p.V69G)	Pathogenic	Likely Pathogenic/VUS	Not found	c.1397+2_1397+3insT	VUS/Likely Pathogenic	VUS	Not found	F	10500	P
53	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.4168-1G>A	VUS/Likely Pathogenic	Not found	Not found	c.4168-1G>A	VUS/Likely Pathogenic	Not found	Not found	M	17503	D
58	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.3067A>T	VUS/Likely Pathogenic	Not found	Not found	c.4996delC (frameshift)	Likely Pathogenic	Not found	Not found	F	6476	P
70	Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps	DYSF (NM_003494.3)	c.2995T>C (W1017R)	VUS/Likely Pathogenic	VUS	Not found	c.2995T>C (W1017R)	VUS/Likely Pathogenic	VUS	Not found	M	13502	P+D
77	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227.3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathogenic	(1, 86-88)	c.1822C>A (p.P577T)	VUS/Likely Pathogenic	VUS	Not found	M	799	D+P
79		GNE (NM_001128227.3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathogenic	(1, 86-88)	c.95T>C (p.M32T)	VUS/Likely Pathogenic	VUS	Not found	M	1880	D+P
81	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227.3)	c.2179G>A (p.V727M)	Pathogenic	Likely Pathogenic/Pathogenic	(1, 86-88)	c.1822C>A (p.P577T)	VUS/Likely Pathogenic	VUS	Not found	F	210	D+P
83	GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles	GNE (NM_001128227.3)	c.124C>T (p.R11W)	Pathogenic	Likely Pathogenic	(145-148)	c.827T>G (p.F276C)	VUS/Likely Pathogenic	Not found	Not found	M	1415	D+P
30	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achilis contractures; Most-affected muscles:		c.1848_1850delCCT (p.L617del)	VUS/Likely Pathogenic	VUS	Not found	c.1848_1850delCCT (p.L617del)	VUS/Likely Pathogenic	VUS	Not found	M	455	P+D

	Hip extensors and adductors, ankle dorsiflexors.												
33	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achilis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors.	COL6A2 (NM_001849.3)	c.1591G>A (p.G531S)	VUS/Likely Pathogenic	VUS	Not found	c.1970-9G>A	Pathogenic	Pathogenic/Likely Pathogenic	(149-153)	M	5467	P
34	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achilis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors.	COL6A2 (NM_001849.3)	c.1900G>A (p.E634K)	VUS/Likely Pathogenic	Not found	Not found	c.1970-2A>G	VUS/Likely Pathogenic	Not found	Not found	F	215	P
36	Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achilis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors.	COL6A3 (NM_004369.3)	c.8301_8303delCTT (p.Y2767_F2768del)	VUS/Likely Pathogenic	Not found	Not found	c.8301_8303delCTT (p.Y2767_F2768del)	VUS/Likely Pathogenic	Not found	Not found	F	615	P+D
119	Filaminopathy-features: Difficulty getting up from ground, Winging of scapula; Most-affected muscles: Mild Upper and lower girdle weakness	FLNC (NM_001458.4)	c.5278G>A (p.G1760S)	Likely Pathogenic	VUS	(10, 154)	c.6043G>C (p.V2015L)	VUS/Likely Pathogenic (South Asia MAF: 0.0061%)	Not found	Not found	M	500	P
113	Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCB (NM_000232.4)	c.544A>C (p.T182P)	Likely Pathogenic	VUS	(140)	c.181A>G (p.K61E)	VUS/Likely Pathogenic (novel)	Not found	Not found	F	6800	P
115	Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors	SGCB (NM_000232.4)	c.335A>T	VUS/Likely Pathogenic (novel)	Not found	Not found	c.335A>T	VUS/Likely Pathogenic (novel)	Not found	Not found	F	7650	P
117	TRIM32-proteinopathy features: Difficulty getting up from ground, Calf hypertrophy; Most-affected muscles: Mild upper and lower girdle weakness	TRIM32 (NM_001099679.2)	c.59G>T (p.C20F)	VUS/Likely Pathogenic	Not found	Not found	c.59G>T (p.C20F)	VUS/Likely Pathogenic	Not found	Not found	F	1708	P+D